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ABSTRACT 
Adipose tissue is distributed across the body as a characteristic depot to 
serve timely energy demands. Adipocytes are the functional units of 
adipose tissue (AT) maintain glucose and lipid homeostasis, a robust 
physiological system regulated precisely by complex network of 
molecular stimuli to achieve the energy demands in both fed and fast 
state. Adipocytes are most versatile cells which efficiently synthesise fat, 
store fatty acids safely and release them upon requirement through three 
well-coordinated processes termed lipogenesis, lipid storage and lipolysis. 
These processes are highly sensitive to nutritional and hormonal stimuli 
and respond via proteins and/or miRNA regulation. Dysregulation leads 
to various metabolic complications like obesity, insulin resistance (IR), 
type 2 diabetes (T2D), cardiovascular disorders (CVD), metabolic 
syndrome and cancer. AT related complications are physiologically 
interlinked and can affect other metabolic organs like liver, heart, muscle 
etc. Hence, it is important to understand the mechanisms regulating 
adipocyte differentiation, lipid storage, lipolysis and signalling to improve 
our understanding on adipose tissue in metabolism. This thesis describes 
the newly identified miR-192* as regulator of adipocyte lipid metabolism, 
miR-221-3p as a novel regulator of ANGPTL8 in human adipose tissue 
and investigates the function of ANGPTL8 in cultured adipocytes.   
 
We studied the expression of miR-192* in visceral adipose tissue (VAT) of 
two obese subject groups. In VAT of cohort, I (morbidly obese group 
undergoing bariatric surgery) we found negative correlation between 
miR192* with serum triglyceride (TG) and positive correlation with high-
density lipoprotein (HDL) concentration. In cohort II (less obese patients) 
miR-192* negatively correlated with the body mass index (BMI). 
Overexpression of miR192* in cultured adipocytes revealed reduced 
expression of the main adipocyte differentiation marker proteins perilipin 
1 and aP2 (adipocyte protein 2) with marked reduction in TG content. 
Transcriptome profiling of adipocytes expressing miR-192* revealed 
impact on central genes of lipogenic pathway. Altered mRNA expression 
Abstract 
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of these genes were validated by qPCR and western blotting. We showed 
that SCD (stearoyl coenzyme A desaturase-1) and ALDH3A2 (aldehyde 
dehydrogenase 3 family A2) are direct targets of miR-192*.   
 
In study II, we addressed the regulation of ANGPTL8 by miR-221-3p 
under inflammatory stimuli. An interesting positive correlation was 
observed between mRNA expressions of ANGPTL8 and ADIPOQ 
(adiponectin), GLUT4 and fatty acyl synthase diacylglycerol O-
acyltransferase 1 in subcutaneous (SAT) and visceral AT (VAT). 
ANGPTL8 mRNA expression was significantly reduced upon 
inflammation-mimicking conditions with concomitant induction of miR-
221-3p expression in cultured adipocytes. We showed that miR-221-3p 
physically targets the 3’UTR of ANGPTL8 and reduces its protein 
expression. VAT biopsy analysis from obese subjects (cohort II, n=19) 
and SAT biopsies from subjects varying from lean to obese (cohort III, 
n=69) showed a negative correlation trend between ANGPTL8 and miR-
221-3p. Significant negative correlation was found between ANGPTL8 
and miR-221-3p expression in morbidly obese subgroup of SAT samples 
(cohort III, n=22) before bariatric surgery, which interestingly 
disappeared after 2-year post surgery weight loss resulting in a significant 
reduction of miR-221-3p. ANGPTL8 negatively correlated with the AT 
inflammatory marker phospholipase A2 G7, while miR-221-3p showed a 
significant positive correlation with this inflammatory marker.  
 
In the last part, we studied the intracellular function of ANGPTL8 using 
lentiviral shRNA based stable knockdown method in cultured adipocytes. 
This resulted in a moderate but significant reduction of TG accumulation. 
The lipidome analysis presented a decrease in alkylphosphatidylcholines 
(alkyl-PCs) and phosphatidylethanolamine (PE) plasmalogens, as well as 
saturated PCs and PEs. Adipocytes devoid of ANGPTL8 revealed 
enhanced lipolysis, and genes encoding ANGPTL4 and leptin, inducers of 
lipolysis, as well as Cpt1a (Carnitine Palmitoyltransferase 1A), Cpt1b 
(Carnitine Palmitoyltransferase 1B), and PGC-1α involved in FA 
oxidation, were upregulated. Pharmacological treatments inducing 
lipolysis also reduced the expression of ANGPTL8 mRNA.  
Abstract 
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These studies together describe the role of miR-192* in AT lipid 
metabolism, relation between miR221-2p and inflammation in regulating 
ANGPTL8 and a functional role of ANGPTL8 in cultured adipocytes. 
Introduction 
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1. INTRODUCTION 
 
Over the past century, obesity has emerged as a major public health 
concern affecting one third of adults and one in five children across the 
globe. Obesity is a major risk factor for the progression of IR, T2D and 
strongly associated with CVD, NAFLD (non-alcoholic fatty liver disease), 
dyslipidaemia and several cardiometabolic complications1. Positive 
energy balance is the major cause for obesity generally driven by intake 
of high-calorie diet, sedentary life combined with genetic predisposition 
and other socioeconomic factors. AT buffers the energy fluctuation by 
safely storing fat during abundance and releasing it during starvation. It 
also performs endocrine and various physiological functions. AT is a 
multifarious tissue composed of preadipocytes and mature adipocytes 
along with adipocyte precursor cells, numerous microvascular and 
immune cells. Anatomical distribution of AT plays a vital role in 
determining its impact on metabolism. AT can be classified into central 
AT (visceral and subcutaneous fat mass from upper abdominal region) 
and peripheral AT (femoral fat from hip and gluteal region). Excess 
central fat, especially VAT, contributes to a higher rate of lipolysis, IR and 
proinflammatory cytokines relative to SAT2. It has been reported that 
visceral fat cells in vitro show elevated lipid synthesis and lipolysis 
compared to subcutaneous adipocytes2-4. VAT secretome contributes to 
elevated serum TG concentrations which may result in hepatic insulin 
resistance and/or steatosis 5,6. miRNAs are small non-coding RNA 
molecules with the length of 19-23 nucleotides. They regulate gene 
expression by targeting mRNA. Resulting in degradation or translational 
repression7. miRNAs have been reported to play a significant role in 
adipose tissue biology. Several miRNAs, including miR-143, miR-30c, 
miR-148a, miR-26a and b promote adipogenesis8-11 and miR-27b, miR-
130 and miR-375 have been reported to inhibit adipogenesis by targeting 
major adipogenic regulators12-14. miRNAs are closely linked to metabolic 
diseases like T2D and obesity15,16. Altered expression of miRNAs in AT, 
pancreas and liver have shown to be associated with obesity and 
Introduction 
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metabolic disorders17-19. miRNAs could induce IR in AT by affecting 
adipocyte function or via stimulating local inflammation. Several obesity- 
related WAT miRNAs like miR-25, -93, -106b family and miR-221 have 
shown positive correlation with insulin resistant clinical parameters20,21. 
miR-221 is negatively associated with mRNA coding tumour necrosis 
factor alpha (TNF-α) and directly targets ADIPOR1. which could 
contribute to the progression of IR21-23. miR-192 has been previously 
associated with liver disease, T2D and cancers24-26.  
ANGPTL8 is a family member of ANGPTL protein family. It is highly 
expressed in both adipocyte and liver and plays an important role in TG 
trafficking. It is highly induced upon refeeding, insulin treatment and acts 
as an inhibitor of lipoprotein lipase (LPL) in concert with ANGPTL327-29. 
siRNA-mediated knockdown of ANGPTL8 causes a reduced TG content in 
the AT of mice27. Recent studies have reported elevated plasma levels of 
ANGPTL8 in obesity, IR and T2D30-32. ANGPTL8 was found to be highly 
expressed upon insulin treatment in vivo in human WAT. Indicating a 
possible independent intracellular role in adipocytes33,34. Despite major 
advances in ANGPTL8 research, its intracellular function in adipocytes is 
not well understood. 
The rise in prevalence of obesity has gathered interest in the biology of 
WAT. A comprehensive understanding of the cellular and molecular 
regulation underlying obesity, IR and T2D is crucial for the development 
of new therapeutic interventions.      
Review of the literature 
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2. REVIEW OF THE LITERATURE 
2.1 Adipocyte biology 
 
2.1.1 Adipocyte function  
 
2.1.1.1 Adipose tissue 
Adipose tissue is a complex organ which regulates and maintains whole 
body energy homeostasis, along with endocrine functions. Adipose tissue 
accounts for 20% of the total body weight in a healthy human being with 
BMI 2535. Adipose tissue in mammals is classified into two subtypes: 
White adipose tissue (WAT) and brown adipose tissue (BAT). Brown 
adipose tissue differs from WAT by the presence of characteristic 
adipocytes with multiple smaller lipid droplets and relatively high 
number of mitochondria. BAT dissipates heat by oxidising stored TGs 
through highly expressed uncoupling protein 1 (UCP1)36. WAT is 
characterized by the presence of mature adipocytes with huge unilocular 
lipid droplets which account for more than 90% of the tissue mass. Along 
with mature adipocytes, WAT contains pre-adipocytes and adipocyte 
precursor cells and other cell types including endothelial cells, fibroblasts, 
macrophages and leucocytes. WAT is further subdivided into two 
categories based on the stereotypical distribution: Visceral adipose tissue 
(VAT) and subcutaneous adipose tissue (SAT). Regardless of their 
histological resemblances VAT and SAT are reported to have different 
depot-specific metabolic roles2. The perception of adipocyte biology two 
decades ago was limited to its conventional function as fat repository to 
provide mechanical support and thermal insulation. Discovery of leptin in 
the year 199437 uncovered adipose tissue as a functional endocrine organ 
and gave insights to the critical roles of AT in human physiology.  
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2.1.1.2 Energy storage 
Adipocytes are evolved to store surplus amount of energy in the form of 
neutral TGs. These TGs can hold more energy per unit mass than protein, 
carbohydrate or glycogen.  Oxidation of one gram fat can yield 9 
kilocalories (kcal) of energy whereas carbohydrates and proteins can only 
release 4 kcal/gram38. TGs are nonpolar in nature and can be stored 
safely in adipocytes in anhydrous form to prevent lipotoxicity to 
neighbouring tissue39. As an energy storing entity, adipocytes efficiently 
store TGs after feeding and secrete FFAs during starvation. The complex 
bidirectional nutrient storage and mobilization are regulated by two 
important biological processes called lipogenesis and lipolysis. 
 
2.1.1.3 Triglyceride metabolism 
Dietary fat is the main source of FFAs for TG synthesis. Fat is digested in 
the gastrointestinal tract by the action of pancreatic hydrolytic enzymes 
to yields FFAs. Epithelial cells of small intestine absorb FFAs, re-esterify 
then to TGs and integrate them into chylomicrons. TG containing 
chylomicrons enter portal circulation via the lymphatic system. 
Lipoprotein lipase (LPL) in the adipose tissue hydrolyses TGs to release 
FFAs from circulating lipoproteins and facilitates their entry into 
adipocytes40. LPL is critical in lipoprotein metabolism. Apart from adipose 
tissue, it is highly expressed in liver, muscle and heart tissue. LPL activity 
is carefully coordinated in a tissue-specific manner to meet varying 
energy needs. LPL is a rate-limiting enzyme regulated by post-
translational mechanisms which include protein-protein interactions with 
apolipoproteins and members of angiopoietin like protein family 
(ANGPTL)40. FFAs taken up by adipocytes from circulation are re-
esterified to TG. De novo lipogenesis (DNL) is a concurrent process 
involving fatty acid synthesis from acetyl coenzyme A (acetyl-CoA) and 
subsequent biosynthesis of TG. Glucose entry to plasma stimulates the 
secretion of insulin from pancreas. Insulin facilitates the entry of glucose 
into adipocytes via GLUT1 and GLUT4 and further activates various 
glycolytic and lipogenic signalling cascades and triggers the expression of 
Review of the literature 
 
 18 
sterol regulatory element-binding protein 1 (SREBP1) which is a master 
regulator of TG synthesis41. Acetyl-CoA and malonyl-CoA derived from 
glucose are used as substrates to generate palmitate in a crucial step of 
DNL catalysed by acetyl-CoA carboxylase (ACC) and fatty acid synthase 
(FAS). Diacylglycerol acyltransferase (DAG) catalyses the final and only 
committed step of the sequential esterification process to yield TG42.  
During energy deprivation adipocytes undertakes a shift towards lipolysis 
where stored TGs in lipid droplets (LDs) are hydrolysed to FFAs and 
glycerol to be used as energy source by other tissues. Lipolysis is highly 
regulated through hormonal and biochemical cues. Catecholamine and 
glucagon are primary inducers of lipolysis. Catecholamine initiates 
lipolysis by binding beta-adrenergic receptors on plasma membrane.   
These receptors coupled with Gs-proteins stimulate adenylyl cyclase to 
produce cyclic AMP (cAMP). Protein kinase A (PKA) is activated upon 
cAMP binding43 and it further phosphorylates hormone sensitive lipase 
(HSL) and perilipin (PLIN). Upon phosphorylation, HSL is translocated 
from cytosol to the LD surface 44-47. In a parallel action, PLIN facilitates LD 
remodelling to provide more surface area and enhances the activity of 
HSL on the surface of LDs48,49. TGs are then sequentially hydrolysed to 
diacyl glycerol (DAG) and monoacyl glycerol (MAG) releasing one FA in 
each step to finally yield glycerol. The enzymatic process is catalysed by 
adipocyte triglyceride lipase (ATGL), HSL and monoacyl-glycerol lipase 
respectively50. Hydrolysed FFAs are oxidized within the AT or released 
into portal circulation and taken up by other organs as energy substrate. 
Glycerol on the other hand is transported to the liver for 
gluconeogenesis51. 
 
2.1.1.4 Endocrine function 
White adipose tissue is a major endocrine organ secreting a wide range of 
bioactive molecules termed adipokines37,52 which regulate systemic 
metabolic functions and regulate crucial biological processes like insulin 
sensitivity, immune response, blood pressure, bone mass, thyroid 
function, haemostasis and reproductive function53. Recent studies have 
reported a growing number of secretory molecules and their relevance for 
Review of the literature 
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the various physiological functions of adipose tissue 54. Discovery of leptin 
in 199455 and cloning of adiponectin in 199556 were major 
breakthroughs. Leptin is a satiety hormone secreted by white adipocytes 
targeted to hypothalamus where it regulates energy balance by inhibiting 
appetite37,57,58. Apart from its satiety role, leptin has also been shown to 
regulate reproductive organs59,60. Some evidence show that it modulates 
glucose homeostasis in the β-cells of pancreas by regulating expression 
and secretion of insulin61. Adiponectin is one of the important adipokine 
synthesised and secreted from adipocytes in relatively high 
concentrations (~10-30 μg/ml or about 0.01% of plasma proteins)62. It is 
well known for its insulin sensitizing, anti-inflammatory and 
cardiovascular protective effects63-67. Adiponectin primarily targets liver, 
activates AMP activated protein kinase to negatively regulate 
gluconeogenesis68,69 and increases hepatic insulin sensitivity independent 
of AMPK by upregulating hepatic ceramidase activity70. Apart from the 
liver, adiponectin targets skeletal muscle where it has been shown to 
increase the phosphorylation of ACC, glucose uptake and fatty acid 
oxidation by activating (AMPK) pathway63,71. Many other adipokines like 
resistin and chemerin are thought be of adipocyte origin. However, recent 
evidence has suggested that they are expressed in different cell types 
within adipose tissue and exert pleiotropic functions 72-74
Review of the literature 
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Figure 1. Lipogenesis and lipolysis. Lipid metabolism and distribution 
controlled by adipose tissue. Lipogenesis is a process by which carbohydrates are 
converted into fatty acids and become a substrate for the biosynthesis of TG in 
adipocytes. Lipolysis works in the reverse way, breaking down TG to free fatty 
acids (FFAs) and glycerol which are either oxidized or secreted. The absorption 
of circulating FFAs by liver, muscle and other tissues is a primary process of lipid 
sorting. Both lipogenic and lipolytic pathways respond to nutrition and 
hormones such as insulin, norepinephrine and glucagon. Hence, a refined 
regulation of lipogenesis and lipolysis is essential for energy homeostasis and 
insulin sensitivity. cAMP, cyclic adenosine monophosphate; AR, adrenergic 
receptor; PKA, protein kinase A; IR, insulin receptor. This figure is modified from 
Luo, L. Liu, M., The Journal of Endocrinology; 2016; 231(3): R77-R9975. 
 
2.1.2 Role of adipose tissue in metabolic pathophysiology 
 
2.1.2.1 Adipose tissue distribution and turnover 
Dysfunction of adipose tissue is strongly associated with severe metabolic 
complexities like obesity, T2D, metabolic syndrome and lipodystrophy. 
WAT is systematically distributed across the body. Specific location of 
WAT defines its identity and primary function. In humans, accumulation 
of intra-abdominal WAT or visceral adipose tissue (VAT) is associated 
with obesity- linked comorbidities. AT from this depot is highly 
metabolically active and dysregulation significantly increases the risks for 
metabolic disorders76. On the other hand, SAT relatively poses less risk 
and has been reported to exert protective metabolic functions4. Reason 
behind differences in fat distribution among individuals remains to be 
addressed. However, several factors like genetic predisposition77, sex 
hormones78, usage of glucocorticoids79 and epigenetics80,81 play a vital role 
in determining the location of excess fat derived from over feeding. 
Adipocyte turnover is a continuous process which relies on the balance 
between adipogenesis and apoptosis. Total adipocyte number is 
determined during childhood and adolescence and remains constant 
through life. AT relies on adipocyte progenitor cells from stromal vascular 
fraction (SVF) as a source for regeneration. Average lifespan of an 
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adipocyte in an adult is approximately 10 years with 10% of SAT 
replaced annually82. 
 
2.1.2.2 Altered lipid mobilization, sorting and storage 
Efficient FA uptake in postprandial state is a very important function of 
adipocytes to avoid adverse systemic effects of high plasma FA 
concentrations83. FAs are important physical components of plasma 
membrane lipids and active energy substrates. They play roles as second 
messengers and are implicated in skeletal and hepatic tissue insulin 
resistance84.  Now it is well documented that AT storage capability is 
crucial to avoid FA- based lipotoxicity in target cells85. However, AT lipid 
buffering capacity is impaired in obesity due to inability to respond to 
postprandial state and in lipodystrophy due to the lack of AT83. FA 
mobilization after TG lipolysis characterizes the other section of FA 
homeostasis. It is well documented that disturbed lipolysis interrupts the 
bioavailability of FAs. LPL plays a major role in regulating intravascular 
and lipolysis. Various LPL mutations abolish production of the LPL 
transcript or lead to unstable transcripts. Some missense mutations 
prevent secretion of LPL from cells, others interfere with the formation of 
unstable or catalytically active homodimers86. Loss of LPL activity causes 
familial chylomicronaemia syndrome, marked by elevated levels of 
plasma TG87. After crossing the endothelial barrier, several FA binding 
proteins facilitate FA incorporation into TG and LD-associated proteins 
efficiently package TG to LD. Hence LPL activity and normal TG synthesis 
and efficient fat storage pathways are crucial to avoid FA spill over which 
eventually leads to ectopic fat storage.
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Figure 2. Lipid metabolism and storage in normal and dysfunctional 
adipocytes.  
A. Healthy adipocytes store and metabolize surplus circulating lipids and glucose 
in the inert form of TG in the lipid droplets. Fatty acids can be trafficked via 
lipolysis when required. Pancreatic insulin initiates de novo lipogenesis as well as 
the absorption and storage of circulating lipids. The secretion of adipokines by 
the adipocytes contributes to systemic metabolic regulation. 
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2 B. Abnormal TG storage in hypertrophic or dysfunctional adipocytes is 
connected with basic fatty acid mobilization, lowered glucose uptake and de novo 
lipogenesis, and lipotoxic diacylglycerols and ceramides are accumulated in 
distant tissues. Changes in these metabolic states are partly due to IR. 
Dysfunctional adipocytes are characterized by lowered production of some 
lipokines as well as altered adipokine profile. Taken together, the increased flux 
of FAs from adipocytes induces systemic metabolic dysfunction. Adaptive and 
adverse effects are marked in green and red, respectively. HSL, hormone-
sensitive lipase; ATGL, adipose triglyceride lipase; MGL, monoglyceride lipase; 
ACC, acetyl-CoA carboxylase. This figure is adapted and modified from 
Vegipoulos et al., EMBO Journal: 2017 Jul 14;36(14):1999-2017 
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2.1.2.3 Adipocyte hypertrophy and hyperplasia 
Adipocyte hypertrophy is characterized by the presence of large lipid-
laden adipocytes due to expansion in cell size beyond 800 pL, the normal 
volume range. On the other hand, hyperplasia is a process where 
relatively smaller adipocytes are newly differentiated from the 
preadipocyte pool of SVF88. Both adipocyte hypertrophy and hyperplasia 
are important characteristic features of AT expansion upon nutrient 
influx82,88. Prolonged positive energy balance, genetic predisposition and 
various environmental factors contribute to expansion of AT89. The risk of 
developing insulin resistance (IR) and T2D goes hand in hand with the 
increased adipose tissue mass and fat deposition90. There is an inverse 
quantitative relation between lower rate of adipocyte production and 
higher grade of hypertrophy. Subjects with hypertrophy are shown to 
generate 70% less adipocytes per year compared to those with 
hyperplasia91. Enlarged adipocyte volume correlates with serum insulin 
levels, insulin resistance and elevated risk of developing T2D92. 
Hypertrophy is associated with AT inflammation, AT fibrosis and ectopic 
fat deposition82,93-95. Hypertrophy initiates cellular stress and activates Jun 
N- terminal kinase (JNK), nuclear factor-kB (NF-kB), Mkk4 and other 
stress inducible master regulators96,97 which activate the transcriptional 
and protein phosphorylation cascade leading to an abrupt release of pro 
inflammatory secretome from adipose tissue which consists of pro-
inflammatory cytokines and chemotactic signalling molecules like Il-6, 
TNF-α, interleukin 1 beta (IL1β), monocyte chemoattractant protein 1 
(MCP1) and others. This condition further leads to local and systemic 
inflammation98. Hypertrophic adipocyte expansion may lead to hypoxic 
condition causing elevated levels of hypoxia-inducible factor 1α (HIF1α) 
initiating AT fibrosis in association with local AT inflammation99. 
Hyperplasia, on the other hand, is generally considered healthy 
expansion of AT where new relatively smaller adipocytes are formed. A 
typical hyperplastic expansion of AT maintains an anti-inflammatory state 
with elevated levels of regulatory T cells, M2 AT macrophages, and 
exhibits high insulin sensitivity and adequate vasculature for 
expansion100. 
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2.1.2.3 Lipodystrophy 
Lack or entire absence of metabolically active adipose tissue defines 
lipodystrophy. Intensity of lipodystrophy can be determined by the 
degree of AT deficiency, which can be acquired or originates due to 
genetic abnormalities101. AT deficiency leads to ectopic deposition of TG 
in liver or skeletal muscle causing reduced whole-body insulin sensitivity 
and organ dysfunction102,103. Defective AT storage elevates circulating 
levels of TG, cholesterol and other metabolically active lipid species, 
leading to atherosclerosis and CVD, as reported in AT deficient Seipin 
knockout mice104 and in patients suffering from congenital generalized 
lipodystrophy105. In addition to lipid storage defects, adipokine and 
cytokine levels are generally altered in lipodystrophy. Reduced levels of 
both adiponectin and leptin are reported in generalized lipodystrophy106. 
 
2.1.2.4 Adipocyte Inflammation 
Adipose tissue has emerged as a biologically active organ linking 
metabolic, endocrine and immune functions to maintain whole body 
homeostasis. A wide range of immune cells are abundantly present in 
adipose tissue stromal vascular fraction which makes them the second 
most abundant cell type after mature adipocytes. Immune cells residing 
in adipose tissue play an important housekeeping role. They clear detritus 
and apoptotic cells to maintain adipose tissue homeostasis in non-obese 
conditions107. However, excess fat accumulation alters the immune cell 
pools in adipose tissue by increasing macrophages, neutrophils, mast 
cells, B and T lymphocyte activity and populations108. Unlike normal 
inflammatory response which is triggered by an infection, adipose tissue 
inflammation is associated with a chronic low grade sterile inflammation 
where slight increase in circulatory pro-inflammatory factors are seen 
which might not be clinically evident109. Despite low severity, 
inflammation caused by obesity can exert substantial effects on metabolic 
pathways which may lead to IR110,111. Secretion of pro-inflammatory 
molecules from dysfunctional adipocytes initiates the migration of 
monocytes from systemic circulation to AT where they eventually 
differentiate into macrophages96. These infiltrated cells in turn enhance 
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the inflammatory status by secreting similar pro-inflammatory molecules 
resulting in both local and systemic inflammation98. 
 
2.2 MicroRNAs 
 
MicroRNAs(miRNA) are noncoding 22 nucleotides long small RNA 
molecules of endogenous origin systematically evolved in eukaryotes to 
cut down the redundant genetic transcripts112-115. miRNAs regulate 
diverse cellular processes including cell proliferation, differentiation and 
survival by specifically targeting complementary mRNA transcripts 
causing either degradation or translation repression113,116-119. The first 
miRNA lin-4 was discovered in Caenorhabditis elegans in 1993113 and the 
first mammalian miRNA let-7 was identified seven years later114. These 
two studies initiated genomic research which lead to the identification of 
many miRNA and noncoding RNA species113,114,120-122. Functional 
validation of these miRNAs has led to an improved understanding of cell 
biology at the molecular level. 
 
2.2.1 MicroRNA biogenesis 
Biogenesis of miRNAs in humans is highly regulated by four important 
enzymes Drosha, Exportin 5, Dicer and Argonaut 2 (AGO2) described in 
Fig 3. A majority of the miRNA encoding genes are located in intronic 
regions with their own promotor segments. miRNA is transcribed by RNA 
polymerase II to give rise to a long (around 1kb) primary miRNA (pri-
miRNA) transcript120,123. A typical pri-miRNA consists of 33-39 nucleotide 
long hairpin stem124 and single stranded RNA overhangs at both  5’ and 3’ 
end. The first step of the maturation process is initiated in the nucleus. A 
microprocessor complex containing Drosha (RNAs III endonuclease) 
processes the pri-miRNA and DiGeorge syndrome critical region 8 
(DGCR8), a cofactor, helps in RNA binding125 and recognizes cutting 
sites. Drosha cuts the region spanning the stem-loop of pri-miRNA 
releasing a hairpin shaped RNA of ~65 nucleotides in length (pre-
miRNA)126. A nuclear transport complex of Exportin 5 and GTP binding  
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Figure 3. MicroRNA biogenesis. Biogenesis of microRNAs (miRNAs) generally 
with transcription of miRNA parent gene by by RNA polymerase II to create a 
primary miRNA (pri-miRNA) hairpin, which is then taken up by the Drosha–
DGCR8 (DiGeorge syndrome critical region 8) complex which gives rise to 
precursor miRNAs (pre-miRNAs). exportin 5 transports these molecules into the 
cytoplasm, where they further undergo cleavage by Dicer–TRBP (TAR RNA-
binding protein 2) and are mounted into Argonaute 2 (AGO2)-containing RNA-
induced silencing complexes (RISCs) to dampen downstream target gene 
expression. This figure is adapted and modified from Li Z, Rana TM., Nat Rev 
Drug Discov. 2014 Aug;13(8):622-38 
 
Nuclear protein RAN-GTP together transport the pre-miRNA to cytoplasm 
in a GTP-dependent manner127-129. In cytoplasm, Dicer (RNAs III type 
endonuclease) and TAR RNA binding protein (TRBP) bind the pre-miRNA 
and Dicer cleaves near the terminal loop releasing a ~22 nucleotide 
miRNA duplex130,131. This RNA duplex has two potential mature miRNA 
strands, miRNA in 5’ and miR* or miR-3p in the 3’ end132. miR*/3p 
originating from the 3’ strand was earlier reported to be less frequently 
expressed. However, strand selection is not obligatory as alternate (miR*) 
strand selection has been reported in miRNA isoform sequencing study133. 
The mechanism for strand selection by RNA-induced silencing complex 
(RISC) during pri-miRNA processing could be partially explained by the 
model where (model 1) similar thermodynamic features of ds-miRNA 
duplex termini may lead to selection of both strands and (model 2) in the 
case of strands with dissimilar thermodynamic property, strand with 
relatively higher thermodynamic stability is favoured for processing134,135. 
In the following step, RNA duplex is successively loaded to (RISC). 
miRNA processing in RISC is mediated by argonaute protein (AGO) 
family of proteins along with many cofactors like TRBP (or PACT).  After 
miRNA duplex loading, pre-RISC complex along with Ago proteins 
cleaves the passenger strand to give rise to mature miRNA. 
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2.2.2 MicroRNA function 
 
After processing, miRNA is successfully loaded into miRNA induced 
silencing complexes (miR-RISC). Argonaute family proteins (AGO) serve 
as a major function unit of miR-RISC. In mammals, there are four AGO 
proteins AGO 1-4, which mediate mRNA repression. AGO2 is the only 
member of the AGO family that functions in RNAi causing mRNA 
degradation136-138. Through RISC complex, miRNA executes two ways of 
gene silencing, mRNA degradation and translational repression139. In 
animals, miRNAs recognize and partially bind target mRNAs via their seed 
sequence between nucleotides 2-8139,140. Following target recognition, 
miRNA induces deadenylation via GW182 which recruits effector proteins 
like poly(A)-binding protein (PABP) and additional deadenylase 
complexes, PAN2-PAN3 and CCR4-NOT complexes141-143. After 
deadenylation, decapping inducers including DDX6 are assembled onto 
the CCR4-NOT complex, initiating decapping by DCP2. In the final step, 
XRN1 exonucleolytically cleaves the mRNA from 5’-3’144,145. Three general 
mechanisms have been suggested for miRNA mediated translation 
repression. (i) Repression at initiation of translation: GW182 dependent 
PABP dissociation from poly-(A) tail disrupts the structure formed by the 
interaction between eIF4G and PABP. mRNAs without poly(A) tail are 
also repressed by miRNA or GW182 tethering146,147. (ii) GW182 can also 
exert translational repression by recruiting CCR4-NOT translation 
inhibitor complex148. (iii) miRNAs can dislodge eIF4 from target mRNA 
which in turn inhibits ribosome binding149,150. The mechanisms mentioned 
above are not completely independent. They may occur alongside, overlap 
with each other, or take place with different kinetics to enhance the 
comprehensive silencing effect. 
 
2.2.3 MicroRNAs in adipocyte biology 
 
2.2.3.1 MicroRNAs in adipocyte differentiation 
miRNAs play a central role during the fate of adipocytes. Increasing 
number of studies carried out in vivo and in vitro in both human and 
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mouse models have reported the integral role of miRNAs during adipocyte 
formation and function. Inhibition of Drosha and Dicer, key proteins of 
miRNA biogenesis have been reported to inhibit adipocyte differentiation 
in human mesenchymal stem cells and inhibition of Drosha in in 3T3-L1 
has been shown to block adipogenesis151,152. miR-143 is the first miRNA 
reported to be involved in human adipogenesis. Interestingly, the effect of 
its direct target ERK5 on adipocyte formation was not known before8. 
Direct targeting and regulation of the master regulator of adipogenesis, 
PPAR gamma by miR-27b was identified in 2009153. Several anti-
adipogenic miRNAs include miR-130 which directly targets PPAR 
gamma13, miR-138 which targets EID-1, a cofactor which binds to PPAR 
gamma to enhance its transcriptional activity154 and miR-375, which 
directly targets and represses AdipoR2155. Furthermore, many pro-
adipogenic miRNAs have been identified. miR-30c facilitates the 
regulation of adipokines: it represses two targets, PAI-1 and ALK2, from 
different signalling pathways9. The combined action of miR-17-5p and 
miR-106 has been shown to regulate the balance between osteogenic and 
adipogenic differentiation by targeting BMP2156. miR-26a and miR-26b 
are upregulated in early adipocyte differentiation. They target sheddase 
ADAM metalloprotease domain 17 (ADM17/TACE), which upregulates 
UCP1 expression11. A well-known promoter of adipogenesis, miR-148a, 
directly targets WNT1, which is a well-known inhibitor of adipogenesis157.  
 
2.2.3.2. MicroRNAs in obesity 
Numerous studies have profiled miRNA expression levels between obese 
versus lean AT in both mice and humans. In a diet-induced obese mice 
study, out of 574 detected miRNAs, only 35 miRNAs were found 
differentially expressed158. Moreover, several miRNA profiling studies in 
human WAT have identified miRNAs which might be dysregulated in 
patients with obesity along with or without T2D. Nevertheless, further 
studies with in vitro experimental validation in different adipocyte cell 
systems have revealed miRNAs involved in obesity (Table 1). Apart from 
overfeeding, genetics plays an important role in obesity. However, in 
human WAT, the degree of differential expression of miRNAs is 
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significantly smaller compared to the relative expression of mRNAs159, and 
altered miRNA levels associated with obesity in humans positively 
correlate with those in the WAT of obese mice affected by genetics or high 
fat diet158. Some of the miRNAs differentially expressed in human WAT 
are summarized in Table 1. Discrepancies are found in the miRNA 
expression in different adipocyte depots. In miRNA expression profiling 
from omental and subcutaneous WAT of either overweight or obese 
subjects, 16 miRNA transcripts out of 106 showed depot specific 
expression and high expression levels in omental compared to 
subcutaneous WAT15. Further studies are needed to identify more miRNAs 
differentially expressed in human WAT and their possible role in obesity.  
 
 
Table 1. miRNAs dysregulated in obesity 
 
miRNA Species and/or 
depot 
Expression 
status 
Phenotype 
and or 
function 
Study 
miR-21 Human/subcutaneous Upregulated ⇑ Not 
established 
171 
miR-130 Human/subcutaneous Upregulated ⇑ Not 
established 
13 
miR-146b Human/subcutaneous 
and visceral 
Upregulated ⇑ Not 
established 
159 
miR-222 Human/visceral Upregulated ⇑ Not 
established 
169 
miR-324-
3p 
Human/ AT/MCS Upregulated ⇑ Induces 
adipogenesis 
163 
miR-519d Human/subcutaneous Upregulated ⇑ Induces 
PPAR-alpha 
160 
miR-221 Human/subcutaneous Up/down    ⇑⇓ Targets 
ADIPOR1, 
EST1 
21,165 
Let7a/d Human/subcutaneous Down           ⇓ Not 
established 
166 
miR-17-5 Human/visceral Down           ⇓ Not 
established 
170 
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miR-26a Human/subcutaneous Down           ⇓ Associated 
with 
lipolysis, 
secretion of 
CCL2 and 
TNFα 
166,167 
miR-29-b Human/subcutaneous Down           ⇓ Associated 
with TNFα 
expression 
168 
miR-125a Human/visceral Down           ⇓ Not 
established 
173 
miR-126 Human/subcutaneous Down           ⇓ Inhibits 
CCL2 
166 
miR-132 Human/visceral Down           ⇓ Regulates 
immune 
system 
170 
miR-141 Human/visceral Down           ⇓ Targets 
YWHAG 
164 
miR-143 Human/subcutaneous Down           ⇓ Not 
established 
171 
miR-150 Human/subcutaneous Down           ⇓ Not 
established 
160 
miR193b Human/subcutaneous Down           ⇓ CCL2 
secretion 
166 
miR-200b Human/visceral Down           ⇓ Not 
established 
172 
miR-220a Human/visceral Down           ⇓ Not 
established 
172 
miR-520 Human/visceral Down           ⇓ Targets 
RAB11A 
164 
miR-1275 Human/visceral Down           ⇓ Targets ELK-
1 
161,162 
This table is adapted and summarized from Arner et al160., Brandao eta al161, JA 
Deiuliis162. 
 
2.2.3.3 MicroRNAs in adipose tissue inflammation 
Many miRNAs have been reported to regulate AT inflammation. miR-132, 
which is known to be downregulated in visceral WAT in obese subjects163, 
triggers NF-κB of B- cells initiating transcription of IL-8 and CCL2 (a key 
factor involved in obesity-induced inflammation) in mature adipocytes in 
vitro and in human primary adipocytes164. Several miRNAs which are 
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otherwise expressed equally in WAT are altered in obesity and have been 
reported to regulate human WAT inflammation by reducing CCL2 
secretion from macrophages and adipocytes165. miRNA-223 knockout 
mice, when fed with high fat diet, developed severe systemic insulin 
resistance and AT inflammation. miR-223 directly targets an important 
macrophage polarizing factor Pknox1 which reduces diet-induced AT 
inflammation166. Reduced expression levels of miR-221, a family member 
of miR-221-3p, one of the main targets of this study, negatively correlated 
with TNF-α in mature adipocytes originated from mesenchymal stem cells 
of obese female subjects23. Many more miRNAs directly or indirectly 
regulate AT inflammation either by inducing the secretion of adipokines 
and or regulating macrophage activation160. 
 
2.2.3.4 Role of microRNAs in insulin resistance (IR) and T2D  
Insulin resistance is the main pathological condition tightly associated 
with T2D. In this condition the target cells lose the ability to respond to 
insulin stimulation. T2D is a complex disorder which is characterized by 
impaired glucose tolerance, defect in β cell function and hyperglycaemia. 
In recent years, many studies have reported the involvement of miRNAs in 
β cell development, insulin secretion and insulin signalling cascade 
related to IR. Several well studied miRNAs like miR-7, miR-9, miR-15a/b, 
miR-34a, miR-124a, miR-195 and mi-376 have been reported to regulate 
glucose homeostasis and insulin production167,168. Insulin growth factors 
(IGF1 and IGF2) play an important role in regulating IR and T2D169,170. 
miR-1 has been reported to regulates the expression of IGF-1-R1171 and 
IGF-1172. miR-320 has been shown to regulate the expression of IGF-1 in 
endothelial cells and to regulate IR in 3T3L-1cells173. Study by Agarwal et 
al. describes that the miR-135a markedly decreases the IRS-2 protein 
expression and miR-135a knock-down has been shown to increase the 
expression of both IRS-2 transcript and protein expression174. miRNAs 
miR-320173, miR-126175 and miR-29176 have been documented to regulate 
PI3K subunit expression which may ultimately cause IR. GLUT4, a major 
glucose transporter is also regulated by number of miRNAs leading to 
lowered glucose uptake. miR-133 has been reported to regulate GLUT4 
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expression via targeting KLF15 in cardiomyocytes177. Interestingly, 
reduced expression of miR-21 was seen in insulin resistant adipocytes and 
the same study showed that over expression of miR-21 led to insulin-
stimulated translocation of GLUT4 in insulin resistant 3T3L1 
adipocytes178. 
 
2.2.3.5 Circulating microRNAs  
Cell-free miRNAs are found distant from their origin in circulation 
generally embedded within exosomes, HDL and RISC179,180. A significant 
number of circulating miRNAs originate from AT. 7,000 mRNAs and 140 
miRNAs have been detected in exosomes secreted from the 3T3-L1 cell 
line181. In a recent study, miRNA expression profile from exosomes of fat 
specific Dicer KO mice showed a significant decrease of 419 miRNAs out 
of the 653 detected compared to WT control182 including several miRNAs 
that are reported to be highly expressed in AT like miR-16, miR-201, miR-
221 and miR-22222,183,184. miRNAs might mediate the communication 
between adipocytes in AT via microvesicles, regulating transcription, TG 
synthesis, adipocyte growth, size and lipid storage185-187. Moreover, AT 
derived exosomal miRNAs may exert both paracrine and endocrine 
effects182. 
 
2.2.3.6 MicroRNA 192-3p 
miR-192*/3p is derived from antisense 3’ arm of the miR-192 precursor 
located in chromosome 11-q13.1. Only few studies so far have reported 
functional characterization of miR-192*. Expression levels of miR-192* 
were depleted upon gliadin peptide treatment in cultured fibroblasts 
obtained from coeliac disease patients, including upregulation of MMPs 
via gluten elicit response in coeliac disease fibroblasts188. Both miR-192-3p 
and miR-192-5p are involved in downregulating the farnesoid X receptor 
(FXR, NR1H4), a ligand-activated transcription factor regulating bile acid 
homeostasis both in liver and intestine. Especially, miR-192-3p has been 
shown to target the NR1H4-3’ UTR supressing its expression and its target 
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genes, OSTα/β and OATP1B3189. miR-192-3p has been recently reported 
to be dysregulated in human rectal cancer tumour samples190. 
 
2.2.3.7 MicroRNA 221-3p 
miR-221-3p is a miR-221/222 family member originating from antisense 
3’ arm of the miR-221 precursor located in chromosome X-p11.3. This 
family of miRNAs are implicated in many adipocyte metabolic 
dysfunctions158,191. miR-221 has been shown to supress ADIPOR1 
expression, thereby affecting adiponectin signal transduction and insulin 
sensitivity of adipocytes192. miR-222 targets GLUT4 and could affect 
insulin sensitivity in gestational diabetes193. A miRNA screen performed 
on adipocytes differentiated from human mesenchymal stromal (MCS) 
cells reported the blunted expression of miR221-3p compared to control 
(undifferentiated) MCS194. Combined interactive analysis between most 
dysregulated miRNAs and mRNAs has predicted that miR-221-3p might 
target PGC1-α and phosphoinositide-3-kinase regulatory subunit 1 
(PIK3R1)194. Elevated expression of miR221-3p has been projected as a 
potential biomarker for acute myocardial infarction195. Dysregulation of 
miR-221-3p is also reported in various forms of cancer. Overexpression of 
miR-221-3p along with miR-222-3p and miR106b-25 cluster has been 
linked with NASH-associated liver carcinogenesis196. Moreover, miR-221-
3p has been reported to target THBS2, which is an inhibitor of lymphatic 
metastasis in cervical cancer197. 
 
2.4 Angiopoietin like 8 (ANGPTL8) 
 
Angiopoietin like 8 is a member of Angiopoietin-like protein (ANGPTLs) 
family. Till date eight members of ANGPTLs have been discovered 
(ANGPTL1-8). The nomenclature of ANGPTLs derives from the structural 
similarities with angiopoietins, which are well known regulators of 
angiogenesis. Based on the independent findings, ANGPTL8 is also 
referred as C19orf80, RIFL27, Lipasin28, betatrophin and hepatocellular 
carcinoma associated gene TD26. ANGPTL8 is a functional protein 
expressed in WAT, BAT and liver, and its expression is induced by 
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feeding, insulin and thyroid hormone. The protein is implicated in various 
biological processes, mainly lipid metabolism27-29, T2D198 and 
inflammation199. 
 
2.4.1 ANGPTL8 Gene structure and protein motifs 
Human ANGPTL8 gene (C19orf80) is localized on chromosome 19p13.2 
embedded in the intron of DOCK6 and encodes ANGPTL8 mRNA 
transcript (NM_018687.6). Mouse ANGPTL8 gene is termed GM6484 and 
is located on chromosome 9. Both transcripts span four exons translating 
198 amino acid leading to a ~22-kDa protein (Fig. 3) Both human and 
mouse poly(A) RNA sequence analysis has reported a single ANGPTL8 
transcript. Human ANGPTL8 is 73% identical and 82% similar to the 
murine protein200. ANGPTL8 apparently originated due to gene 
duplication of an inherited DOCK gene before evolutionary mammalian 
radiation. Generally, ANGPTL family proteins share a similar protein 
domain pattern with a prominent N-terminal domain and a C-terminal 
fibrinogen-like domain connected through a linker region (Fig. 3). 
ANGPTL8, unlike its family members, lacks the fibrinogen-like domain at 
its C terminal and possesses only the coiled-coil domain29. Sequence 
alignment analyses have revealed that the ANGPTL8 N-terminal domain is 
significantly similar to the N-terminal domains of both ANGPTL3 and 
ANGPTL4, which are responsible for binding and inhibiting LPL 
activity200,201. Both human and mouse ANGPTL8 include a secretion signal 
sequence at the N terminus and are predicted to have two coiled-coil 
domains and a cleavage site between amino acid 15 and 16202,203. 
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Figure 3. Gene structure of human ANGPTL8. A) Gene location of ANGPTL8 
on chromosome 19p13.2, B) ANGPTL8 transcript (NM_018687.6). This figure is 
adapted and modified from Tseng et al., Int J Mol Sci. 2014 Dec 
18;15(12):23640-57  
 
 
2.4.2 Physiological expression 
 
ANGPTL8 is expressed in liver, WAT and BAT of both human and mice. 
According to Zhang et al, ANGPTL8 is highly expressed in liver and BAT 
in mice, while in humans, ANGPTL8 is reported to be mainly expressed in 
liver200. Following studies also reported ANGPTL8 expression in mice BAT 
and its elevation in cold temperature204. Parallel expression profile study 
by reported similar observations in mice but reported a prominent 
expression also in WAT 27. ANGPTL8 mRNA expression is reported in both 
liver and subcutaneous adipose tissue (SAT) of human subjects34.  
Expression analysis from Human Protein Atlas study has documented the 
enrichment of ANGPTL8 in liver and AT though breast and kidney tissue 
also express it to some extent205.  
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2.4.2.1. Regulation of expression 
Expression of ANGPTL8 is nutritionally regulated. It is highly induced 
upon refeeding while fasting supresses its activation27,200. Studies from 
Ren et al. have demonstrated approximately 8 and 12-fold increase in 
fasted/refed mice WAT and liver, respectively27. In several dietary 
transcriptome studies in mice and human, differential expression of 
ANGPTL8 could be observed. Microarray analysis in mice showed a 
decrease of 13% and 6% in ANGPTL8 mRNA expression in the liver after 
6 and 12 hrs fasting, respectively206. In a dietary manipulation study, 
human subjects were put under calorie restriction for 8 weeks followed by 
2 weeks of high fat diet. During the low-calorie period, ANGPTL8 
transcript expression in subcutaneous WAT (sWAT) decreased 41% 
compared to control subjects who did not go through calorie restriction. A 
continued 2-week refeeding period dramatically increased sWAT 
ANGPTL8 level by 148%, suggesting that ANGPTL8 is induced upon 
refeeding and nutritionally regulated207.  
Insulin is a strong inducer of ANGPTL8 expression in both AT and liver. 
ANGPTL8 transcript expression is dramatically induced by insulin during 
energy storage scenario, especially during TG formation and/or 
lipogenesis. An in vitro study has shown elevated ANGPTL8 mRNA 
expression after insulin induction along with glucose in cultured HepG2 
cell208. Our previously reported insulin clamp study conducted on 
hyperinsulinemic human subject had recorded an induced expression of 
AT ANGPTL8 transcript. This specific effect was reconfirmed in vitro in 
SGBS adipocytes where insulin stimulated ANGPTL8 mRNA expression by 
10-fold and protein expression by 32%34. Thyroid hormone had also been 
shown to upregulate ANGPTL8 expression in HepG2 cells209. Irisin, a small 
polypeptide myokine upregulates ANGPTL8 mRNA expression in 3T3-L1 
adipocytes and intraperitoneal injection of recombinant irisin to mice also 
induced ANGPTL8 expression in AT210. siRNA-mediated knockdown of 
PPAR-γ and SREBP-1c resulted in reduced expression of ANGPTL8 in 3T3-
L127 and HepG2 cells211 respectively, displaying a putative direct positive 
regulation on ANGPTL8. Moreover, tumor necrosis factor-alpha (TNF-α), 
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a prominent proinflammatory cytokine, downregulates ANGPTL8 
expression in 3T3L-1 adipocytes 27. 
 
2.4.2.2. Secretion and intracellular localization 
ANGPTL8 bears a predicted N-terminal signal sequence from 1-20 amino 
acids suggesting that it is a secretory and/or membrane bound protein212. 
ANGPTL8 can be detected in serum in both human and mice and its levels 
in serum has been analysed in association with serum TG, VLDL, HDL and 
other metabolic markers, which is discussed in section (2.1.1.3). Cellular 
ANGPTL8 has been shown to colocalize along with lipid droplet and/or 
lipid droplet-linked cellular compartments209. ANGPTL8 localization has 
been reported at vesicular structures of varying shapes and sizes. In 
hepatoma cells, ANGPTL8 is distributed as small vesicle-like structures 
typically less than 1μm in diameter in the cytoplasm209. Larger ANGPTL8 
vesicles are shown to localize with the lipid droplet protein perilipin 2 
(PLIN2) or/and lysosome associated membrane protein 2 (LAMP2)209. 
 
2.4.3 Function of ANGPTL8 
Studies reporting functional characterization of ANGPTL8 started 
emerging during 2012. Three different research groups independently 
identified this protein and named as Lipasin, RIFL27,28 and betatrophin. So 
far, ANGPTL8 has been studied by various groups as a major modulator of 
lipid metabolism along with the studies showing its role in insulin 
resistance208, autophagy209 and regeneration of pancreatic beta cells 
(controversial). In vitro studies have revealed that serum TG levels were 
decreased when ANGPTL8 was knocked down, and overexpression of 
ANGPTL8 increased serums TG in mouse model studies27,29,200. Increased 
plasma TG levels in the presence of ANGPTL8 are explained by its ability 
to inhibit LPL leading to the slowing down of plasma TG clearance28. This 
concept was strengthened when ANGPTL8 was reported to decrease 
postprandial LPL activity in heart and skeletal muscles 213. Inactivation of 
ANGPTL8 in mice through an antibody elevated the postprandial heparin 
LPL activity214. In addition to ANGPTL8’s significant role in fed state, loss 
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of ANGPTL8 had been reported to distinctly reduce the absorption of 
VLDL-derived TG in AT upon refeeding.  
Circulating levels of ANGPTL8 has been studied extensively in the context 
of human pathophysiology. Serum ANGPTL8 levels in humans were 
discovered to be low after overnight fasting29 and elevated at 2 hours after 
refeeding32. Increased circulating ANGPTL8 levels were detected in T2D, 
child obesity with insulin resistance, T1D and gestational diabetes. 
However, due to the lack of detailed and consistent evidence, the 
connection between circulating ANGPTL8 and obesity and diabetes still 
needs to be established. Several ANGPTL8 sequence variations have been 
shown to be associated with lipid profiles by human genome wide 
association studies signifying that ANGPTL8 involved in both promoting 
and partitioning postprandial flux of TGs into AT213. ANGPTL8 in 
adipocytes plays a lipogenic function and promotes TG storage. ANGPTL8 
expression positively correlates with adipogenesis in both human and 
mice and ANGPTL8 knockout mice showed reduced lipid storage in 
adipocytes during adipogenesis27. ANGPTL8 expression is higher in AT 
compared to muscle and heart. However, lack or inhibition by ANGPTL8 
increases LPL activity in muscle and heart but not in WAT27,29,213,214. 
ANGPTL8 expression is induced by insulin plus glucose in 3T3-L1 
adipocytes; however it was not detected as a secreted protein in the 
culture medium.27 Interestingly, both feeding and cold exposure resulted 
in simultaneous rise in ANGPTL8 expression and the activity of LPL in 
WAT and BAT, respectively27,29,204,215,216. These data and more studies in 
parallel have revealed that ANGPTL8 is responsible for fine-tuning LPL 
activity and substrate partitioning by inhibiting LPL activity upon the 
fasting-feeding metabolic shift200,213. Apart from TG metabolism, ANGPTL8 
had previously been suggested to stimulate pancreatic beta-cell 
proliferation. However, subsequent studies failed to reproduce the 
original finding; hence the concept of ANGPTL8 enhancing pancreatic 
beta-cell content has been invalidated217,218. 
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 Figure 4. ANGPTL8 homology with ANGPTL3 and ANGPTL4. ANGPTL8 shares 
homology with N’ terminal domain of ANGPTL3 which is crucial for serum TG 
regulation. ANGPTL8 also shares homology with N’ terminal domain of ANGPTL4 
which facilitates LPL binding. Spotted lines indicate homologous domains. LPL, 
lipoprotein lipase; SE1, a segment that mediates LPL binding. SP, signal peptide. 
This figure is adapted and modified from Zhang R, Biochem Biophys Res Commu. 
2012 Aug 10;424(4):786-92 
 
 
2.4.4 The model of ANGPTL8, ANGPTL3 and ANGPTL4 
 
TG trafficking is tightly regulated by LPL. During starvation, LPL activity is 
low in WAT and high in muscles. In contrast, in fed state, LPL activity 
increases in WAT and decreases in muscle. However, the mechanisms 
regulating the tissue specific function of LPL in fed/fast cycle remains to 
be addressed. The current scientific findings are depicting a combined 
working model where ANGPTL8, ANGPTL3 and ANGPTL4 are distributing 
the circulating TGs to appropriate organs under different physiological 
conditions214. ANGPTL8 activates ANGPTL3 to inhibit LPL activity in heart 
and skeletal muscle, while ANGPTL4 inhibits LPL activity in WAT. Fasting 
state elevates ANGPTL4 activity and downregulates ANGPTL8, and 
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subsequently LPL activity is reduced in WAT but increased in muscle. 
Hence, TGs are diverted towards muscle for oxidation29,213,219. On the 
other hand, refeeding reduces ANGPTL4 but upregulates ANGPTL8 
activity. This increases LPL activity in WAT but reduces it in muscle, thus 
TGs are circulated to WAT for storage214  
 
2.4.5 ANGPTL8 in adipocytes and in metabolic diseases  
 
In adipocytes, ANGPTL8 is strongly upregulated upon food intake and 
insulin stimulation, and downregulated by agents inducing lipolysis, like 
forskolin. A study has reported drastic upregulation of the ANGPTL8 
transcript in AT of ob/ob mice relative to wild type mice27,28. ANGPTL8 is 
also expressed in mouse BAT and upregulated during cold exposure204. 
LPL activity is high in both of the above-mentioned conditions in WAT 
and BAT along with elevated expression of ANGPTL8. Hence one could 
argue that ANGPTL8 might possess LPL-independent functions in AT. 
Also, ANGPTL8 expression is strongly upregulated during the 
adipogenesis and its knockdown has been reported to hamper the process 
of adipocyte differentiation in 3T3-L1 cells27. Existing literature suggest 
that ANGPTL8 levels are upregulated in circulation during diabetes. 
Generally, diabetes is depicted by hypertriglyceridaemia, lower 
postprandial lipaemia and HDL cholesterol220. Given the ANGPTL8-3-4 
model, one could reason that LPL inhibition by ANGPTL8 in heart and 
muscle resulting in hypertriglyceridemia could be the cause for diabetic 
dyslipidaemia. The question is thus whether diabetic dyslipidaemia could 
be treated by ablating ANGPTL8. Studies suggest that ANGPTL8 KO in 
mice do not have major health problems213; identification of homozygous 
null mutation in humans might reveal insights about the role of ANGPTL8 
in human pathophysiology.  
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2.4.6 ANGPTL8 - unanswered questions 
 
Despite the recent major findings in the field of ANGPTL8 there are 
several crucial aspects to be addressed.  
1. Intracellular function in adipocytes. 
2. Mechanism of LPL inhibition by ANGPTL8.   
3. Tissue specific inhibition of LPL according to the ANGPTL8-3-4 
model221. 
4. Identification of tissue specific transcription factors controlling 
ANGPTL8 expression and their binding sites. 
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3. Aims of the study 
1. To elucidate the functional role of miR192* in adipocyte 
differentiation and TG storage.   
 
 
2. To study the miRNA regulation of ANGPTL8 expression in human 
subjects and Simpson Golabi Behmel Syndrome (SGBS) 
adipocytes.  
 
 
3. To characterize the function of ANGPTL8 in 3T3L1 adipocytes.  
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4. Materials and methods 
4.1 List of published methods 
 
Method  Studies used in 
 
RNA isolation 
 
I, II, III 
Cell culture I, II, III 
Stable overexpression of miR192* in SGBS cells I 
Triglyceride quantification  I, II 
Microarray experiments and data analysis* I 
Bioinformatic analysis* I, II 
Quantitative real time reverse transcription PCR I, II, III 
Validation of microRNA targets I, II 
Antibodies and western blotting I, II, III 
Statistical analysis I, II, III 
Lipolysis assay III 
Lipidome analysis* III 
Staining of lipid droplets III 
Determination of plasma ANGPTL8 protein level* II 
Transfection experiments III 
Microscopy III 
Study subjects* I, II 
VAT biopsies* I, II 
Ethics I, II 
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4.2 Brief descriptions of the methods employed 
 
4.2.1 Cell culture 
4.2.1.1 SGBS (human) cell culture 
SGBS preadipocytes were cultured in Dulbecco's Modified Eagle Medium 
(DMEM) F12 (Sigma-Aldrich, St. Louis, MO) at a 37 °C humidified 
incubator in 5% CO2 and supplemented with 33 μM biotin, 17 μM 
pantothenate, 10% foetal bovine serum (Gibco/Life Technologies, Grand 
Island, NY), 100 I.U./ml penicillin, and 100 μg/ml streptomycin (Sigma 
Aldrich). Differentiation into mature adipocytes was carried out in a 
sequential manner with quick differentiation medium for four days 
followed by 3FC medium in serum-free conditions by employing a 
previously established 14-day protocol222,223. 
 
4.2.1.2 3T3-L1 (mouse) cell culture 
3T3-L1 preadipocytes were cultured in Dulbecco’s Modified Eagle 
Medium (DMEM, Sigma-6429, Sigma-Aldrich, St. Louis, MO) with 10% 
fetal bovine serum (Sigma-Aldrich) and 100 I.U./ml penicillin, and 100 
μg/ml streptomycin (Sigma-Aldrich). After 70% confluency cells were 
transduced with lentiviral particles expressing shRNA targeting Angptl8, 
Clone1: AAGCCCACCAAGAATTTGAGA, Clone2: 
TATGACAGAGCACTGGAATTC (CSTVRS-MissionTM, Sigma-Aldrich) and 
the transduced cell pools were selected using 3 mg/ml of puromycin. 
Following selection, 3T3-L1 cells were grown till confluency and 
differentiated to mature adipocytes using following steps: Cells were 
treated with 100 nM insulin, 500 μM 3-isobutyl-1-methyl- xanthine 
(IBMX), 250 nM dexamethasone, and 2 μM rosiglitazone in complete 
growth medium for the first 48 h, then replaced with 100 nM insulin and 
2 μM rosiglitazone in complete growth medium for the next 48 h. Fresh 
complete growth medium was then changed every 48 h till day 6–8. 
Mature adipocyte cultures were quality checked for more than 80% 
differentiation from the abundant presence of large cytoplasmic lipid 
droplets then used for experiments. 
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4.2.1.3 Human primary adipocyte culture 
Human subcutaneous preadipocytes obtained from a non-diabetic 
Caucasian male with BMI<30 and age<40 (Zen-Bio, Inc., Research 
Triangle Park, NC) were cultured with the preadipocyte medium (Zen-
Bio, Inc.) in a 37°C humidified incubator with 5% CO2. After growing for 
24 hrs, cells were checked for 100% confluency and differentiated into 
mature adipocytes according to manufacturer’s instructions using 
differentiation medium (Zen-Bio, Inc.). Cells attained round morphology 
and presence of large lipid droplet formation was apparent after two 
weeks of differentiation. Mature adipocytes were incubated with renewed 
adipocytes medium (control) or new medium containing 2.5% 
macrophage conditioned media (MCM). In each treatment, new RPMI 
medium was diluted with adipocytes media to attain identical conditions. 
After 48 h of treatment, the cells were collected and stored at -80°C for 
future analysis. 
 
4.2.1.4 Human monocyte cell culture  
The human monocyte cell line THP-1 (ATCC) was cultured in RPMI 1640 
medium with 10% fetal bovine serum, 2 mM glutamine, 5 mM glucose, 
50 mg/ml Gentamycin and 20 mM HEPES, pH 7.4, at humidified 37°C in 
a 5% CO2 as previously described224. Type 1 macrophage-like state (M1) 
was induced with 0.162 mM phorbol 12-myristate 13-acetate (PMA, 
Sigma Chemical Co., St. Louis, MO) for 24 hrs. Differentiated cells were 
washed with cold Dulbecco’s phosphate-buffered saline and incubated 
with new medium without PMA. Then, differentiated M1 macrophages 
were treated with fresh medium containing 10 ng/ml lipopolysaccharide 
(LPS, Sigma Chemical Co.) for 24 hrs. The LPS-stimulated macrophage 
conditioned media (MCM) was then collected and centrifuged at 400 x g 
for 5 min, (Zen-Bio, Inc.), diluted with adipocyte medium and used to 
induce inflammation in mature human adipocytes as described224. HuH7 
cells were cultured at a 37 °C humidified incubator in 5% CO2, in 
AQMEM medium (Sigma-Aldrich), 10% fetal bovine serum (Sigma-
Aldrich) 100 I.U./ml penicillin, and 100 μg/ml streptomycin (Sigma 
Aldrich). 
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4.2.1.5 Lentiviral transduction 
miR-192* lentiviral constructs shMIMIC® (VHS5841-101207549), or a 
nontargeting miRNA controls (HRM5872, Thermo Scientific) were 
transduced into SGBS fibroblasts.  
Lentiviral particles at a multiplicity of three I.U./cell were infected in 
serum free condition with DMEM mentioned above with 8.0 μg/ml hexa 
dimethrine bromide (Sigma Aldrich). Growth medium was added on top 
after 4 h of incubation. The cells were allowed to grow for 48 hrs, then 
subjected to selection by adding growth medium containing 0.5 μg/ml 
puromycin (Sigma-Aldrich). The cells were expanded in the presence of 
puromycin and then subjected to adipogenic differentiation, during which 
no antibiotic selection was applied. 
 
4.2.1.6 Transfection 
SGBS preadipocytes were transfected with miRNA mimics or a non-
targeting control siRNA (see above) in 6-wells for 24 hrs using the 
RNAiMaxTM reagent (Thermo Fisher Scientific, Waltham, MA). 
Adipogenic differentiation was then induced according to a published 
protocol222 without replacing the transfection complexes. Adipocyte 
cultures were harvested for western analysis after 4 days. 
 
4.2.1.6 Lipolysis assay 
Angptl8 knockdown and control 3T3-L1 cells were incubated under basal 
and isoproterenol (10 μM) treated conditions for 2 hrs, after which the 
cell supernatants were measured for the release of non-esterified fatty 
acids (NEFA) using HR Series NEFA-HR kit (Wako Diagnostics, 
Richmond, VA) according to the manufacturer’s protocol. 
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4.2.2 Gene expression analysis 
4.2.2.1 Total RNA isolation form AT 
Frozen AT biopsies (~200 mg) were thawed on ice to 40C and 
homogenized in 0.6 ml QIAzol® lysis solution QIAGEN (Germantown, 
MD). Total RNA was extracted and purified using miRNeasy® Mini Kit 
QIAGEN (Germantown, MD). Final RNA concentrations were estimated 
with a NanoVue (GE Healthcare Life Sciences Pittsburgh, USA)  
 
4.2.2.2 Total RNA isolation form cell culture lysates 
Cells were lysed directly from culture plates by using RNA lysis buffer 
and vortexed briefly to ensure lysis. Total RNA was isolated using 
PureLink® RNA Mini (Ambion/Thermo Fisher, Waltham, MA) or 
RNeasy® Mini Kit QIAGEN (Germantown, MD). Final RNA 
concentrations were estimated NanoVue (GE Healthcare Life Sciences 
Pittsburgh, USA)  
 
4.2.2.3 Microarray data analysis 
Background noise correction within arrays was done using a normal 
exponential convolution model225. Array data were normalized by 
quantile process to confirm that intensity values have the same empirical 
distribution through arrays. Box plot and density plot of array data were 
used for quality control. Data were log2 transformed. Differential 
expression between SGBS-miR192* and SGBS-NT adipocytes was 
equated by empirical Bayes statistics226. P-values were corrected for 
multiple testing by the Benjamini–Hochberg method. The data is 
available at http://www. ncbi.nlm.nih.gov/geo/ with access code 
GSE62951. 
 
4.2.2.4 qRT-PCR 
Total RNAs isolated from cell cultures were reverse transcribed using 
Exiqon Universal® or VILO® reverse transcriptase (Invitrogen, Carlsbad, 
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CA) kits. Real time qPCR was performed in LightCycler®480 (Roche 
Applied Science, Penzberg, Germany) using specific miRNA primer 
(Exiqon), gene-specific primer pairs (Sigma Aldrich) and the Roche 
SYBRGreen® master mix. As housekeeping references, 36B4 (acidic 
ribosomal phosphoprotein) and SDHA (succinate dehydrogenase 
complex, subunit A) genes were used. The crossing points (Cp) values 
were evaluated for every amplification curve using Second Derivative 
Maximum Method227. ΔCp value was initially calculated by subtracting 
the Cp value for equivalent endogenous controls in each sample from the 
Cp value for each sample and target gene. Fold changes compared with 
the endogenous control were then determined by calculating 2-ΔCp. 
Duplicates and positive and negative controls were included. 
 
4.2.2.5 TaqMan qRT-PCR 
Isolated RNA samples were reverse transcribed using TaqMan® 
microRNA Reverse Transcription Kit (Life Technologies/Applied 
Bioscience, Foster City, CA) or VILO® reverse transcriptase (Invitrogen, 
Carlsbad, CA) kits. miRNA expression was analysed with miRNA specific 
TaqMan® MicroRNA assays by using RNU44 as a reference gene. Gene 
expression analysis was performed using commercially available and pre-
validated TaqMan® primer/probe sets: RNU44 (assay# 001094) and 
ribosomal protein lateral stalk subunit P0 (RPLP0, Hs99999902_m1) 
were used as endogenous controls for miRNA and gene expressions, 
respectively. 
 
4.2.3 Protein detection and quantification 
4.2.3.1 Western blot 
Cultured cells were lysed in radioimmunoprecipitation assay buffer 
(RIPA) with protease inhibitor cocktail, sonicated, and centrifuged to 
remove the insoluble material. Protein concentrations were subsequently 
measured from the supernatant. Protein samples were then boiled for 5 
min along with reducing Laemmli sample buffer. Proteins were subjected 
to electrophoresis on SDS poly- acrylamide gels and electrotransferred on 
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Hybond-C Extra nitrocellulose membrane. Samples on nitrocellulose 
membrane were treated with primary antibodies followed by horseradish 
peroxidase conjugated secondary antibodies to visualize the proteins of 
interest using enhanced chemi-luminescence on Fujifilm X-ray films. The 
detected bands were then digitally scanned and analysed using Image J 
software228. 
 
4.2.3.2 ELISA 
The quantification of ANGPTL8 in heparin plasma was determined by 
using a commercial ELISA assay (Aviscera Bioscience, Santa Clara, CA) 
 
4.2.4 Lipid analysis 
 
4.2.4.1 Triglyceride quantification assay 
SGBS adipocytes were lysed using RIPA buffer with protease inhibitor 
cocktail and centrifuged at 12,000 rpm for 15 min at 40C. The 
supernatant was then subjected to triglyceride analysis using the GPO-
PAP Triglyceride assay kit (Cobas, Roche/Hitachi, Tokyo, Japan). The 
data was normalized to the total protein concentration. 
 
4.2.4.2 Lipid droplet staining. 
Mature adipocytes were washed and fixed with 4% paraformaldehyde 
followed by permeabilization with 0.1% Triton X-100 in phosphate-
buffered saline. Cells were then stained with 100 nM Bodipy 493/503 
(Molecular Probes/Life Technologies, Eugene, OR) for one hour. Nuclei 
were stained with 4',6-diamidino-2-phenylindole (DAPI). Cells were 
imaged using Zeiss Axio Observer Z1 microscope (Carl Zeiss Imaging 
Solutions GmbH, Oberkochen, Germany).  
 
  Materials and methods 
 53 
4.2.4.3 Lipidome analysis 
Lipids were subjected to direct flow injection electrospray ionization 
tandem mass spectrometry (ESI–MS/MS) in positive ion mode using the 
analytical setup and strategy described in229. A precursor ion of m/z 184 
was employed for phosphatidylcholine (PC), sphingomyelin (SM) 229 and 
lysophosphatidylcholine (LPC)230. The following neutral losses were 
applied: PE 141, phosphatidylserine (PS) 185, phosphatidylglycerol (PG) 
189 and phosphatidylinositol (PI) 277231,232. PE-based plasmalogens (PE 
P) were quantified based on the principles explained in233. Lipid species 
were interpreted according to the newly published proposal for 
shorthand notation of lipid structures that are derived from mass 
spectrometry234. Glycerophospholipid species annotation was based on 
the hypothesis of even numbered carbon chains. 
 
4.2.5 Molecular biology 
 
4.2.5.1 Cloning of luciferase constructs 
SCD and ALDH3A2 3’UTR constructs were acquired from GeneCopoeia 
(Rockville, MD). The miR-192* target sequences SCD and ALDH3A2 
were mutagenized using QuikChange XL kit (Agilent, Santa Clara, CA). 
The ANGPTL8 3’UTR DNA was PCR amplified and cloned downstream of 
firefly luciferase in the dual luciferase vector pEZX-MT06 (GeneCopoeia, 
Rockville, MD). Mutagenesis to remove the predicted miR-221-3p binding 
site was performed by using the Quick Change XL kit (Agilent, Santa 
Clara, CA). 
 
4.2.5.2 Dual luciferase assay 
HuH7 cells in 12-wells were transfected with the Luc-3’UTR constructs 
along with miRNA mimics (100 nM) or a non-targeting control siRNA 
(100 nM) by using Lipofectamine 2000TM (Invitrogen, Carlsbad, CA) for 
24 hrs. Cells were lysed in passive lysis buffer (from the luciferase kit) 
and firefly and Renilla luciferase activities were measured by using the 
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Dual Luciferase kit (Promega, Madison, WI). The firefly values were 
normalized by using the Renilla values. 
 
4.2.6 Subject recruitment  
 
4.2.6.1 Cohort 1:(I) 
Morbidly obese subjects (BMI 46.8 ± 6.3) were recruited from the group 
of patients undergoing laparoscopic bariatric surgery in Peijas Hospital of 
the Hospital District of Helsinki and Uusimaa. The following criteria were 
considered during the process of recruitment: (i) age 18–65 years; (ii) no 
reported acute or chronic disease excluding obesity or obesity related 
diseases such as T2D, non-alcoholic fatty liver disease, CVD and/or 
hyperlipidaemia; Elimination criteria were: (i) alcohol abuse (>20 
g/day), (ii) hepatotoxic medications or herbal products usage, and (iii) 
lactation or pregnancy. The subjects were examined in the morning after 
an overnight (10–12 h) fast one to two weeks before the surgery. Height, 
weight, hip and waist circumferences were documented as described235. 
Blood samples were drawn to measure the concentrations of (HDL) and 
(LDL) cholesterol, TG, glucose, C-peptide, and insulin, along with 
alkaline phosphatase (ALP), alanine transaminase (ALT), and aspartate 
transaminase (AST) activities as described236. Prior to operation, patients 
adhered to a 6–12 week of very low-calorie diet (800 kcal/day). Detailed 
clinical characteristics of the subjects are shown in Table 2. 
 
4.2.6.2 Cohort 2: (I, II) 
Subjects were (BMI 31.2 ± 2.5) 17 female cohort, undergoing elective 
gynecological surgery for non-malignant causes in the department of 
Obstetrics and Gynecology, Helsinki University Hospital, were recruited. 
Patients were scheduled for abdominal or laparoscopic hysterectomy, 
diagnostic laparoscopy, salpingo-oophorectomy, enucleation of uterine 
myoma, or laparoscopic colpo-sacro-rectopexyor enucleation of ovarian 
cyst. Causes for surgery comprised uterine myomas accompanied with 
menorrhagia and/or pain, benign ovarian cysts, infertility and 
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dysmenorrhea, or rectocele. Blood samples were collected before the 
surgery and centrifuged to isolate serum and stored at−20 °C. Detailed 
clinical characteristics of the subjects are shown in Table 3. 
 
4.2.6.3 Cohort 3 (II): 
Subjects were recruited at the department of Diabetes, Endocrinology 
and Nutrition and the Department of Surgery of the Hospital “Dr Josep 
Trueta” of Girona (Girona, Spain) Abdominal SAT samples were collected 
from 69 women [Body mass index (BMI) = 39.6 ± 10.9 kg/m2, age = 49 
± 12 years (mean ±SD) during elective surgery (cholecystectomy and 
surgery of abdominal hernia) at the Hospital “Dr Josep Trueta” of Girona 
(Table 4). SAT biopsies were also withdrawn from 22 morbidly obese 
women before (‘baseline-longitudinal’ or ‘pre-bariatric surgery’) and ca. 
two years after surgery-induced weight loss were analysed. (Roux-en-Y 
gastric bypass; Table 4). MicroRNA and gene expressions were measured 
(qRT-PCR) on all AT biopsies as previously explained237. Recruits were 
previously informed and written consent was signed. Subjects were of 
Caucasian origin and their reported body weight was stable for at least 
three months before the study. No systemic diseases were reported other 
than obesity and/or T2D. All participants were devoid of any infections 
one month before entering the study. Liver and thyroid dysfunction were 
specifically excluded. Other exclusion criteria were: i) history of drug or 
alcohol abuse, or serum transaminase activity more than twice the upper 
limit of normal, ii) clinically significant hepatic, neurological, or other 
major systemic disease, including malignancy, iii) age above 65 or below 
25 years, iv) acute major cardiovascular event in the previous 6 months, 
v) an elevated serum creatinine concentration, vi) acute illnesses and 
current evidence of high grade chronic inflammatory or infective 
diseases, and vii) mental illness rendering the subjects unable to 
understand the nature, scope, and possible consequences of this study. 
The study protocol was approved by the Ethics Committee and the 
Committee for Clinical investigation (CEIC) of the Hospital “Dr. Josep 
Trueta” of Girona. 
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4.2.7 Bioinformatics and statistics 
 
Kolmogorov–Smirnov test was used to examine the clinical readouts and 
normality of distribution. Non-normally distributed data are mentioned 
as median (25%–75% percentile) normally distributed data are 
represented as means ± standard error of mean (SEM). Spearman's test 
was used to analyse the correlations between miR-192* and miR-192 
expression levels in VAT. miRNA binding region in the 3’UTR of 
ANGPTL8 mRNA (NM_018687.6) were located by using Targetscan 
(http://www.targetscan.org/vert_71/, Whitehead Institute for 
Biomedical Research, Cambridge, MA). Correlation analysis of miRNA 
and gene were analysed by nonparametric Spearman test in Prism 7 
(GraphPAD, La Jolla, CA) software. Gene expression between human 
study subjects were analysed using Mann–Whitney test in Prism 7 
(GraphPAD, La Jolla, CA) and IngenuityTM pathway analysis software. 
Results of continuous variables are stated as mean±standard deviation; 
p-values <0.05 were mentioned as statistically significant. 
 
Table 2 
 
Anthropometric and biochemical data of Cohort 1 
Bariatric surgery Cohort   
Gender (females/males)  18/9 
Age (years)  48.0 ± 9.7 
Body weight (kg) 133.5 ± 25.9 
Body mass index (kg/m2)  46.8 ± 6.3 
Biochemical parameters  
fP-glucose (mmol/L) 5.8 ± 0.9 
fS-insulin (mU/L)  11.9 (7.3–20.0) 
fS-C-peptide (nmol/L)  1.1 ± 0.40 
fS-LDL cholesterol (mmol/L)  2.8 ± 0.9 
fS-HDL cholesterol (mmol/L)  1.2 ± 0.3 
fS-TG (mmol/L)  1.3 ± 0.5 
fS-ALT (U/L)  34 (22.0–51.5) 
fS-AST (U/L)  30 (24.0–39.5) 
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fS-ALP (U/L)  69 (56.0–82.5) 
 
Table 3 
Anthropometric and biochemical data of Cohort 2 
Gynecologic surgery cohort   
Gender (females/males)  17/0 
Age (years)  46.0 ± 9.5 
Body composition  
Body weight (kg)  85.0 ± 9.0 
Body mass index (kg/m2)  31.2 ± 2.5 
Biochemical parameters  
fS-LDL cholesterol (mmol/L)  3.4 ± 0.8 
fS-HDL cholesterol (mmol/L)  1.4 ± 0.4 
fS-TG (mmol/L)  1.6 ± 2.0 
fS-AST (U/L)  33 (21–145) 
 
Table 4 
Anthropometric and biochemical data of Cohort 3 
Parameters   
N 69 
Age (years) 49 ± 12* 
BMI (kg/m2) 39.6 ± 10.9 
Fat mass (%) 53.4 ± 12.4 
Glucose (mg/dl) 103.4± 35.7** 
HbA1c (%) 5.3 ± 2.1 
Cholesterol (mg/dl) 197.7 ± 36.8 
LDL (mg/dl)  117.7 ± 29.3 
HDL (mg/dl) 57.1 ± 15.0 
Triglycerides (mg/dl) 113 ± 43.4 
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Parameters (BMI<30)  
N 21 
Age (years)  56 ± 13 
BMI (kg/m2) 26.3 ± 2.6 
Fat mass (%) 40 ± 4.5 
Glucose (mg/dl) 99.3 ± 26.0 
HbA1c (%) 5.4 ± 0.6 
Cholesterol (mg/dl) 222.2 ± 40 
LDL (mg/dl) 132.3 ± 25.5 
HDL (mg/dl) 62.3 ± 18.0 
Triglycerides (mg/dl) 106 ± 38.7 
 
Parameter (BMI>30)   
N 48 
Age (years) 46 ± 10 
BMI (kg/m2) 45 ± 7.4 
Fat mass (%) 59.7 ± 9 
Glucose (mg/dl) 105 ± 39.2 
HbA1c (%) 5.1 ± 2.6 
Cholesterol (mg/dl) 187.8 ± 33.1 
LDL (mg/dl) 111.2 ± 28.8 
HDL (mg/dl) 54.9 ± 13.2  
Triglycerides (mg/dl) 115 ± 42.5 
Abbreviations: ALT alanine aminotransferase; ALP, alkaline phosphatase; AST, 
aspartate aminotransferase; BMI. Body mass index; f, fasting; HDL, highdensity 
lipoprotein; LDL low-density lipoprotein; P, plasma; S, serum; TG, triglycerides; 
Data are shown as mean ± SD or median (25%–75% percentile), as applicable. 
*The values represent mean ± SD. BMI, body mass index; HbA1c, glycated 
hemoglobin; HDL, highdensity lipoprotein; LDL, low-density lipoprotein ** Of 
the subjects, 9 were on metformin and 2 on metformin plus insulin therapy. 
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5. Results  
5.1 Study I 
 
The primary objective of Study I was to investigate the molecular 
regulators of AT lipid metabolism, focusing on the function of miR-192* 
in human adipocyte lipid metabolism.  
  
5.1.1 Association between miR-192* expression and adipose tissue 
in human cohorts. 
 
Our miRNA profiling study from VAT of (cohort I) obese subjects 
undergoing bariatric surgery exhibited a negative correlation between 
VAT miR-192* expression and serum TG levels (Fig. 1A, I) and a positive 
correlation with serum HDL cholesterol (Fig. 1B, I) and aspartate amino 
transferase (Table 3, I). miR-192 showed similar correlation trends with 
TG and HDL; however, these were not significant. Positive correlation 
between miR-192* and miR192 suggested similar abundancy of both 
mature miRNAs originating form same pre-miRNA. Insertion of covariates 
such as BMI, age and gender did not significantly alter the correlation 
between miR-192* with HDL/TG (data not shown). No correlation was 
found between miR192* and BMI among morbidly obese subjects. In 
correlation analysis from VAT biopsies of Cohort 2, the lower BMI group 
(31.2±2.5) showed no significance correlation between miR-192* with 
serum HDL, TG or AST (Table 4, I); however, this group displayed a 
significant negative correlation between VAT miR-192* and BMI (Fig. 1D, 
I). Relatively low expression of miR-192* was observed compared to miR-
192 in subgroup of BMI >30 in cohort 2. Target prediction analysis 
suggested numerous genes involved in lipid metabolism which could be 
targeted by miR192*, including peroxisome proliferator activated 
receptor α (PPAR-α), low-density lipoprotein receptor (LDLR), patatin-
like phospholipase domain containing 3 (PNPLA3), Krüppel-like factor 6 
(KLF6), caveolins 1 and 2 (CAV1, CAV2), stearoyl coenzyme A desaturase 
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1 (SCD) and aldehyde dehydrogenase 3 family member A2 (ALDH3A2). 
With the existing data, we further continued to characterise the function 
of the 3 arm species, miR-192*, in adipocytes  
 
5.1.2 Functional characterization of miR192* in SGBS adipocytes  
Stable overexpression of miR-192* (SGBS-miR-192*) or non-targeting 
control (SGBS-NT) were established in SGBS pre-adipocytes using a 
lentiviral vector. Cells were then subjected to adipogenic differentiation. 
Successful overexpression of miR-192* was confirmed by qPCR analysis 
in both pre-adipocytes and mature adipocytes (Fig. 2A, I). SGBS 
adipocytes expressing miR-192* showed less TG storage (25%) than 
control adipocytes (Fig. 2B, I). This phenotype was further supported by 
the altered expression of key adipogenic markers. qPCR analysis revealed 
a marked reduction of GLUT4 mRNA and a negative trend for the AP2 
(statistically not significant) (Fig. 2C, D, I). However, western blot 
analysis showed a significant reduction of AP2 and perilipin 1 (PLIN1) 
protein levels. These results clearly suggest that miR-192* expression in 
SGBS adipocytes caused a defect in adipogenic differentiation and TG 
storage. We performed transcriptome profiling of SGBS adipocytes 
expressing miR192* and NT control (n=4 each) to identify the pathways 
and specific target genes through which miR-192* is causing the defect in 
adipocyte differentiation and TG storage. We found 637 mRNAs to be 
differentially expressed between SGSB-miR192* and SGBS-NT out of 
which 176 mRNAs were downregulated in SGBS- miR-192*. Pathway 
analysis was carried out on differentially expressed genes using the 
IngenuityTM pathway analysis. Over- expression of miR192* affected the 
‘LPS/IL-1 mediated inhibition of RXR function’ and ‘LXR/RXR activation’ 
pathways (Fig. 3, I). Within these pathways, expression of 14 mRNAs 
were considerably dampened, and 13 mRNAs were upregulated in SGSB-
miR192*. Several key lipogenic genes were among the mRNAs which 
were reduced in SGBS-miR-192*, including SREBF1 (sterol regulatory 
element binding protein-1), ACSL3 (acyl-coenzyme A synthetase long 
chain-3), ACSL6, SCD (stearoyl coenzyme A desaturase-1), FABP7 (fatty 
acyl binding protein-7). Several genes from the downregulated pathways 
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were predicted at least by two algorithms to be direct targets of miR-
192*. (Fig. 3, I). In addition to mRNA suppression caused by expression 
of miR-192*, the expression of several mRNAs was elevated in the 
affected pathways, like IL1R2 (interleukin-1 receptor type II), APOH 
(apolipoprotein H), CYP3A5 (cytochrome P450 3A5), C9 (complement 
component 9) and MSR1 (macrophage scavenger receptor 1/scavenger 
receptor A). 
 
5.1.3 Validation of targets of miR-192*  
In the last section, we performed validation experiments to identify and 
confirm miR-192* targets from SGBS-miR-192* and SGBS-NT adipocytes. 
We quantified both mRNA and protein expressions of relevant targets 
through a series of qPCR and western blot experiments, qPCR analysis 
confirmed the downregulation of FABP7, ALDH3A2, SCARB1, ALDH3B2, 
SCD and increased expression of APOH, CYP3A5, and MRS1 mRNAs in 
the SGBS-miR-192* adipocytes (Fig. 4, I). Protein expression of SCD1, 
ALDH3A2, SCARB1 (SR-B1) were significantly reduced in SGBS-miR-
192* compared to the SGBS-NT adipocytes (Fig. 5, I). To confirm 
whether miR-192* physically binds the SCD and ALDH3A2 mRNAs, we 
performed dual luciferase reporter assays. First we cloned the 3’ UTRs 
(miRNA-192* binding) of SCD and ALDH3A2 to luciferase reporter 
construct. miR-192* mimics or non-targeting RNAs were co- transfected 
with luciferase constructs into HuH7 cells followed by optical 
measurement in luminometer. Both SCD and ALDH3A2 reporter 
constructs showed a marked reduction in firefly luciferase activity due to 
direct binding of miR-192* on the respective 3’UTRs. We then introduced 
mutations to check the specificity of miR-192* binding on these UTRs. 
The mutations disrupted the effects of miR-192* on both SCD and 
ALDH3A2 3’UTR reporters, which confirms that SCD and ALDH3A2 are 
directly regulated by miR-192*. 
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5.2 Study II 
 
This study is focused on regulation of ANGPTL8 by miR221-3p under 
inflammation induced condition in adipocytes and influence of miR-221-
3p expression in the context of dysregulated adipose tissue metabolism  
 
5.2.1 ANGPTL8 in context with insulin sensitive and lipogenic 
markers. 
 
In the light of several studies showing the insulin responsiveness of 
ANGPTL8, we analysed correlations of ANGPTL8 gene expression with 
hallmark insulin sensitivity markers like GLUT4 and ADIPOQ. We found a 
significant positive correlation with GLUT4 (r = 0.48 and P<0.0001) in 
female SAT (n=69) of cohort 2 (Fig. 1A, II), and in VAT (r = 0.63, P = 
0.004) of cohort 1 (Fig. 1C II).  In addition, ANGPTL8 positively 
correlated with ADIPOQ in SAT (r =0.43, P =0.0003) and VAT (r =0.49, 
P = 0.03) (Fig. 1B and 1D II). We also found significant correlations in a 
subgroup analysis where BMI >30, and <30 subgroups of cohort 2 were 
assessed distinctly (data not shown). In support to previously published 
data, ANGPTL8 also revealed a significant positive correlation with FASN 
and DGAT1 mRNAs, which are important lipogenic genes. (supplemental 
Fig. 1A and 1B II). 
 
5.2.2 Inflammation, a key modulating factor of ANGPTL8 and miR-
221-3p expression in human adipocytes  
 
It is well known that inflammation is associated with the expression of 
genes stimulated by insulin and it is frequently related to IR status238,239. 
We investigated the possible influence of pro-inflammatory stimuli on 
ANGPTL8 expression in adipocytes. We created a physiologically relevant 
condition where we exposed human primary adipocyte culture to 
conditioned medium of LPS-stimulated THP-1 macrophages (MCM, 
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2.5%) or the corresponding control medium and analysed ANGPTL8 
mRNA expression by qPCR. The pro-inflammatory treatment drastically 
reduced ANGPTL8 expression (by –86%, p< 0.001) (Fig. 2A, II). We also 
validated the suppression of insulin responsive genes Adiponectin (–51%, 
p <0.01) and GLUT4 (–61%, p <0.001) upon treatment with 2.5% MCM 
(Fig. 2A, II). Upregulation of inflammatory facilitators interleukin 6 and 
tumour necrosis factor-α was observed, which increased 13- and 3-fold 
(p<0.01 and p<0.001), respectively (Fig. 2B). Interestingly, treatment of 
2.5% MCM also suppressed mRNA levels of the key lipogenic genes, 
FASN and DGAT1. 
miRNAs modulate the expression of several genes under inflammatory 
conditions240-243.  Our hypothesis was to investigate whether miRNAs are 
regulating ANGPTL8 expression under such conditions. Hence we 
mapped the 3’UTR of ANGPTL8 for putative miRNA binding sites. The 
short 280-nt 3’UTR of ANGPTL8 revealed several miRNA binding sites 
which have previously been linked with insulin resistance, T2D or 
obesity: miR-107, miR-143-3p, and miR-221-3p (Fig. 2C, II). We found 
that only miR-221-3p expression was elevated (2.5-fold, p<0.001) in 
primary adipocytes under inflammatory conditions induced by 2.5% 
MCM treatment (Fig. 2D, II). 
 
5.2.3 miR221-3p physically binds ANGPTL8 3’UTR and regulates its 
expression in adipocytes  
 
We conducted dual luciferase assays to test the direct binding of miR-
221-3p on the ANGPTL8 3’UTR which was previously cloned in Luc 
reporter constructs. Both miR-221-3p and NT mimics along with Luc 
constructs were transfected to HuH7 cells. After 24hr incubation, cells 
were lysed and measured for Luc signal. We observed a significant 
decrease (28.5%, p<0.001) in Luc signal in cells transfected with miR-
221-3p compared to NT controls (Fig. 3A, II), which implies the direct 
binding of miR-221-3p on the ANGPTL8 3’UTR. We also confirmed that a 
mutation introduced into the miR-221-3p binding site successfully 
destroyed the binding capability, indicating the direct binding of miR-
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221-3p to the ANGPTL8 3’UTR (Fig. 3B, II). To further confirm the action 
of miR-221-3p on ANGPTL8 in adipocytes, we transfected miR-221-3p 
mimics and non-targeting siRNA into SGSB preadipocytes and ANGPTL8 
protein levels were measured after 4 days of differentiation. Western 
blotting revealed that the ANGPTL8 protein was dampened by 46% 
(p<0.01) in adipocytes transfected with miR-221-3p compared to non-
targeting control (Fig. 3C and D, II). Interestingly, miR-221-3p 
transfection into SGBS cells also significantly reduced TG accumulation 
(Fig. 1C). 
 
5.2.4 Condition-specific association between miR-221-3p and 
ANGPTL8 in AT in vivo 
 
To investigate the possible relation between miR-221-3p with ANGPTL8 
we analysed the expression of both miR-221-3p and ANGPTL8 in two 
human cohorts. SAT biopsies of cohort 2 consisting of female subjects 
(n=69) (Supplemental Table 1, II) showed a marginal tendency of 
negative correlation between miR-221-3p with ANGPTL8 (r =–0.16, p= 
0.18; Fig. 4A II). VAT biopsies from cohort 1, consisting of 19 women 
(BMI 31.6 ± 3.2) showed a similar tendency (r = –0.25, p =0.3) 
(Supplemental Table 2; Fig. 4B II). Concurrently, subgroup analysis of 
the cohort 2 obese subjects (BMI >30, N = 48) revealed a similar 
correlation trend (r = –0.19, p = 0.18; Fig. 4C III), which was not seen in 
the overweight subcategory (BMI <30, N = 21, r = –0.03; Fig. 4D II). 
We subsequently evaluated the mRNA and miRNA expression in a 
morbidly obese subcategory of cohort 2 (n=22) that had undergone 
bariatric surgery. SAT biopsies were obtained from these subjects prior to 
surgery and after two years of post-operation weight loss follow-up 
(Table 1, II). Substantial weight loss following operation, (BMI from 43.4 
6±5.0 to 29.2 6±5.7, p<0.0001), both serum lipid (HDL and TG) values 
and GLUT4 expression were significantly improved. Likewise, ANGPTL8 
expression showed an increasing trend and miR221-3p expression was 
dampened but the difference was not statistically significant (Table 1, II). 
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However, an interesting observation was that a significant negative 
correlation was found (r =-0.51, p=0.016) between miR221-3p and 
ANGPTL8 in biopsies collected from the morbidly obese subjects before 
bariatric surgery (Fig. 4E, II). This correlation was not observed in post 
weight loss AT biopsies (Fig. 4F, II). This bariatric surgery cohort was 
further subdivided considering with (n=7) or without (n= 15) 
metformin or metformin plus insulin therapy, which revealed a negative 
correlation between miR-221-3p and ANGPTL8 in the non-medicated 
group. Exclusion of the seven medicated patients further strengthened 
the negative correlation of miR-221-3p and ANGPTL8 mRNA (r = -0.70, 
p = 0.003), suggesting that the improved metabolic status and weight 
loss post bariatric surgery may influence the regulatory mechanisms of 
ANGPTL8 expression in AT. 
 
5.2.5 Association between ANGPTL8 and miR221-3p with AT 
inflammation in vivo 
 
In a genome wide transcriptome study, Soronen et al. had previously 
identified that phospholipase A2 G7 (PLA2G7), an inflammatory marker, 
was strongly upregulated in obese insulin resistant subjects33 and was 
also reported in other studies to be induced upon AT inflammation244-246. 
Hence, we quantified PLA2G7 mRNA expression in SAT biopsies of 
Cohort 2. Interestingly, PLA2G7 showed a significant negative (r = -0.50, 
p = 0.01) correlation with ANGPTL8 and positive (r = 0.57, p = 0.006) 
correlation with miR-221-3p (Fig 5A and 5b, II). This further supported 
our hypothesis that inflammation may control the miR-221-3p regulation 
of ANGPTL8 expression in AT. When analysed separately, considering 
PLA2G7 expression, we found a significant difference in ANGPTL8 mRNA 
quantity (p =0.009) and an almost significant trend in miR-221-3p (p 
=0.06) between the PLA2G7 low- and high-expression groups as divided 
at the median (Fig. 5C, II).     
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5.2.6 No direct relation between SAT and circulating ANGPTL8 
levels 
 
Increased ANGPTL8 levels had been associated with obesity related 
insulin resistance and diabetes. Hence, we quantified the ANGPTL8 
protein levels in heparin plasma from a bariatric surgery patient group (n 
=16). We found no correlation between the SAT ANGPTL8 mRNA and 
the plasma ANGPTL8 concentration at baseline (r = –0.13, p = 0.96) nor 
after weight loss (r = 0.020, p = 0.93). As an interesting observation, 
plasma ANGPTL8 levels elevated significantly after the weight loss 
(baseline 105.6 ± 19.9 ng/ml, after weight loss 119.8 ± 17.6 ng/mL; P = 
0.049).     
 
5.3 Study III 
 
This study aims investigates the intracellular function of Angptl8 in 
3T3L1 adipocytes. 
 
5.3.1 Angptl8 knockdown in 3T3-L1 adipocytes alters lipid storage 
and composition 
 
To investigate the function of ANGPTL8 in adipocyte lipid metabolism, 
we established two stable ANGPTL8 knockdown cell pools using 
independent lentiviral shRNA constructs termed as Angptl8 KD1 and 
Angptl8 KD2. ANGPTL8 knockdown cells were carefully grown under 
selection pressure and confirmed for the knockdown efficiency 
(approximately 70-75%) for both KD1 and KD2 by measuring mRNA 
expression by qPCR (Fig. 1A, III). We quantified TGs in the ANGPTL8 
knockdown cells using thin layer chromatography and documented a 18-
19% reduction compared to cells transduced with non-targeting shRNA 
control lentivirus (Fig. 1B, III). We checked the mRNA expression of 
genes encoding TG synthesizing enzymes monoacylglycerol O-
Acyltransferase-1 MOGAT1, diacyl-glycerol O-Acyltransferase-1 (DGAT1), 
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glycerol-3-phosphate acyltransferase-1 (GPAT1) and found no reduction. 
Lipid droplet (LD) staining with Bodipy 493/503 (green) dye showed a 
similar general LD morphology in both Angptl8 KD1, KD2 and control 
cells (Fig. 1C, E, III). We observed a subtle difference in KD1 cells where 
cell size and LD distribution were heterogeneous with many small sized 
LDs in some cells and few large LDs in another cell population (Fig. 1D, 
III).  
To study the comprehensive effect on ANGPTL8 knockdown, we obtained 
total lipid from both ANGPTL8 KD1, KD2 and control cells and performed 
quantitative direct flow injection electrospray ionization tandem mass 
spectrometry (ESI–MS/MS) analysis. The results obtained were analyzed 
independently in KD1 and KD2 with shRNA controls. We found 
disparities in lipid species among KD1 and KD2 and also found 
substantial differences between ANGPTL8 KD1, KD2 and the shRNA 
control. We found a decline of ether phospholipids (alkyl-PCs and PE 
plasmalogens) in the KD cell pools (Fig. 2A–E, III). In addition, some very 
low abundant lipid species like saturated PCs, lysoPCs and PEs, were 
significantly reduced in both Angptl8 KD pools (Fig. 2F–H, III). 
 
5.3.2 Angptl8 knockdown alters lipolysis and lipid oxidation in 
3T3-L1 adipocytes  
 
It is well known that Angptl8 inhibits LPL in circulation together with 
Angptl329. Along with our results which showed reduced TG 
accumulation in Angptl8 knockdown, this encouraged us to analyse the 
intracellular lipolysis in Angptl8 knockdown and control 3T3-L1 
adipocytes when stimulated with isoproterenol (β-adrenergic receptor 
agonist). We measured the release of NEFA in the culture medium. This 
stimulated lipolysis significantly more in both KD1 and KD2 cell pools in 
comparison with the control cell pool. Enhancement of lipolysis was 
observed both in the presence and absence of isoproterenol (Fig. 3A, III). 
Interestingly, we also observed that Angptl8 mRNA expression in naive 
3T3-L1 adipocytes was dampened by both isoproterenol and forskolin 
treatments, known stimulators of adenylate cyclase increasing protein 
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kinase A activity and lipolysis (Fig. 3B, III). Hence, we analysed the genes 
responsible for the regulation of lipolysis. mRNA expression levels were 
measured for Angptl4, Pnpla2, Pnpla3 and hormone sensitive lipase 
(HSL) after inducing lipolysis for 2 hours. Angptl4 mRNA expression was 
significantly elevated in both KD1 and KD2 cell pools relative to non-
targeting controls, while HSL and Pnpla2 expression were not altered. 
We observed an elevated expression of Pnpla3 in KD1, but however not 
in KD2 (Fig. 4A, III). Analysis of relevant genes involved in fatty acid 
oxidation, Ucp1, Cpt1a, Cpt1b and PGC-1α, revelaed a significant 
increase in KD1 and a similar trend in KD2. Cpt1a and Cpt1b were 
upregulated in both KD1 and KD2 cell pools (Fig. 4B, III). We also 
observed the increased expression of Leptin mRNA expression in both 
Angptl8 KD1 and KD2 cells (Fig. 4B, III). 
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6. Discussion 
In this study, we focused on identifying novel regulators of adipose tissue 
lipid homeostasis with special emphasis on miRNA-based regulation. 
With three independent projects, we have discovered the miRNA species 
miR-192* and miR221-3p as modulators of lipid metabolism and 
identified ANGPTL8 as a regulator of adipocyte lipolysis. 
 
We first started investigating miR192*(miR192-3p) based on an 
interesting correlation: Expression of miR-192* in VAT of morbidly obese 
subjects correlated negatively with serum triglyceride content and 
positively with HDL-cholesterol and AST. Expression of miR-192* 
correlated negatively with BMI of another female patient cohort with 
lower BMI. miR-192* originates from the 3’ arm of miR-192, a well-
studied miRNA and shown to be associated in liver disease247,248, type 2 
diabetes15,26 and cancers249,250. However, studies on miR-192* expression 
and function are scarce. We showed that stable overexpression of miR-
192* in cultured SGBS adipocytes reduced TG accumulation and affected 
adipogenic differentiation as established by the low TG content and 
downregulation of adipogenic markers proteins aP2251 (FABP4) and 
perilipin 1252,253. Neither aP2 nor perilipin are direct targets of miR-192* 
but their reduced expression or ablation exerts major physiological 
changes, for example, T87C polymorphism in humans at aP2 locus causes 
reduced gene expression which lowers serum TG levels resulting in 
considerably reduced risk for coronary heart disease and type 2 diabetes 
relative to subjects homozygous for the wild-type allele254. Perilipin 1 is a 
lipogenic factor. Deletion of perilipin 1 in mice resulted in reduced 
adipose tissue mass255,256. It is essential for normal deposition and 
retention of TG in lipid droplets. Through transcriptome profiling and 
pathway analysis of SGBS adipocytes expressing miR-192* or NT-miR, 
two key lipid regulatory pathways ‘LXR/RXR activation’ and ‘LPS/IL-1 
mediated inhibition of RXR function’, were found to be altered. LXR/RXR 
initiation is essential for adipogenic differentiation and TG storage is 
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mediated by PPARγ or C/EBPα in both 3T3-L1 and SGBS cell systems257-
261. Many lipogenic genes from ‘LPS/IL-1 mediated inhibition of RXR 
function’ pathway like SREBF1, FABP7, ACSL3 and ACSL6 were found to 
be downregulated in SGBS cells expressing miR-192*. We confirmed the 
downregulation of SCD1, SCARB1 (SR-B1) and ALDH3A2 at protein level 
by western blotting. More importantly, we showed that SCD and 
ALDH3A2 are direct targets of miR-192*. SCD1 is a highly regulated 
enzyme that catalyses the synthesis of monounsaturated fatty acids 
(MUFAs) from saturated fatty acids derived either from diet or de novo 
lipogenesis. MUFAs are major lipid components of TG, cholesterol esters 
and phospholipids262. Oleate is the primary product of SCD1 and 
comprises up to 45% of free fatty acids in human adipose tissues263. SCD1 
is abundantly expressed in liver and adipose tissue264 and reported in 
other lipogenic tissues265. SCD1 has been shown to regulate lipid 
synthesis and oxidation, hormonal signalling, thermogenesis and 
inflammation. SCD1 knockout mice have shown lowered adiposity, 
increased insulin sensitivity and are not affected by diet induced 
obesity266 . Moreover, lipogenic diet was unable to induce TG synthesis in 
their liver267. Liver specific SCD1 knockout mice were resistant to hepatic 
steatosis and diet-induced obesity. Adipose specific SCD1 knockout mice 
show enhanced GLUT1-mediated glucose uptake and lowered expression 
of adiponectin in AT268. Blocking SCD1 expression in 3T3-L1 adipocytes 
reduced expression of several lipogenic genes resulting in reduced TG 
synthesis269. SCD1 has been shown to regulate inflammatory response via 
modulating DNA methylation in 3T3-L1 adipocytes270. SCD1 expression 
was relatively reduced in morbidly obese human subjects compared to 
overweight subjects271. The above data together suggest an important role 
of SCD1 in lipid synthesis and metabolism. Inhibition of SCD1 expression 
by miR-192* in the VAT could effectively hamper TG synthesis resulting 
in an overflow of non-esterified fatty acids and inflammatory stimuli 
towards the liver.  
Aldehyde dehydrogenase (ALDH3A2 or FALDH), is a fatty acid 
dehydrogenase which facilitates the detoxification of aldehydes from lipid 
peroxidation events by converting long chain aliphatic aldehydes to fatty 
acids272. ALDH3A2 is elevated by insulin, and its expression is 
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downregulated in an animal model with insulin resistance273. Its 
suppression may lead to pathologic effects of altered fatty aldehyde 
metabolism like lipotoxocity, which may lead to insulin resistance and 
proinflammatory signaling in VAT. Scavenger receptor class B, type I (SR-
B1, gene SCARB1) serves as a receptor for high-density lipoproteins 
(HDL) 274. It facilitates the selective uptake of lipids from HDL and is 
expressed in several types of tissues. Its role in adipocytes is not well 
explored. However, it has been shown to facilitate the anti-inflammatory 
action of HDL and to induce glucose uptake by HDL in adipocytes275,276. 
Inhibition of SCARB1 expression may thus influence the anti-
inflammatory and pro-lipogenic functions of HDL in VAT. 
High TG and low HDL-cholesterol are hallmarks of CVD, obesity and 
metabolic syndrome277,278. We found a negative correlation between the 
expression of miR-192* and serum TG, and a positive correlation 
between miR-192* and HDL cholesterol in VAT of morbidly obese 
subjects. However, there was no correlation found with LDL- cholesterol. 
This tempts us to speculate on a possible direct or indirect function of 
miR-192* in regulating HDL and/or VLDL production by the liver which 
is physiologically connected with VAT via portal circulation279. 
Alternatively, it could affect VLDL metabolism to successively influence 
HDL-cholesterol278,280. As a yet another interesting result, we found both 
miR-192* and miR-192 species in the AT of morbidly obese subjects 
positively correlated with AST, a liver enzyme routinely used as a 
biomarker for hepatic damage. This supports the hypothesis that the 
increased expression of miR-192* could result in an abnormal VAT fat 
storage and elevated flux of lipid species towards liver, which may result 
in liver dysfunction281,282.  
 
In a female cohort (cohort 2) with a lower BMI we did not observe any 
correlation between miR-192* with TG, HDL and AST, strongly 
suggesting that the correlations are tightly associated with metabolic 
status of the morbidly obese cohort. Like in the morbidly obese cohort, 
we did not notice correlation with LDL cholesterol. However, we 
observed negative correlation between VAT miR-192* and BMI of (less 
obese) cohort 2 which is consistent with the cultured adipocyte results 
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suggesting that miR-192* downregulates adipogenesis. No similar 
tendency or correlation was observed in the morbidly obese cohort 
(cohort 1). We envision that morbid obesity represents an extreme 
metabolic condition where subtle regulatory changes could not be 
detectable at this point. Comparison of miR-192* levels between the two 
cohorts did not uncover any alterations. However, when cohort 2 (lower 
BMI group) was subdivided based on BMI <30 or >30, lower miR-192* 
expression was seen in the BMI >30 subgroup, further supporting the 
concept that miR-192* reduces lipid storage in adipocytes. 
 
In the fourth study, we show that ANGPTL8 expression in human SAT 
and VAT shows a strong positive correlation with hallmark insulin-
regulated or adipogenic markers. ANGPTL8 is one of the insulin sensitive 
genes involved in lipid metabolism reported in our previous studies33,34. 
This motivated us to investigate its regulation in adipose tissue. We found 
that ANGPTL8 expression positively correlated with major insulin 
sensitizers GLUT4 and ADIPOQ suggesting that ANGPTL8 expression in 
adipocytes might also contribute to insulin sensitivity, and it is consistent 
with the notion that ANGPTL8 promotes white adipocyte lipid 
storage27,213,283. We also found that ANGPTL8 expression positively 
correlated with important lipogenic genes like DGAT1 and FASN.  
There are several controversial reports on serum ANGPTL8 level in 
insulin resistant condition and subjects with T2D. Most reports suggest 
that AGNPTL8 levels are elevated under these conditions31,32,198,284,285 . On 
the contrary, some studies including that of Gomez-Ambrosi et al. 
indicate that ANGPTL8 expression is rather decreased in patients with 
T2D and dyslipidemia198,286. Also, data from Pascual-Corrales et al.287 
suggests that serum ANGPTL8 is elevated after bariatric surgery and not 
due to diet-induced weight loss. This observation is consistent with our 
findings on plasma ANGPTL8 levels in a bariatric surgery cohort, where 
we found that ANGPTL8 expression is downregulated upon adipocyte 
culture under inflammation-mimicking conditions and correlates 
negatively with an inflammatory marker mRNA in morbidly obese 
subjects. Till now detection of ANGPTL8 protein levels in plasma has not 
been well established and the regulation of its secretion, tissue source 
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and protein turnover are main areas to be studied considering the 
suggestion that the liver could be the main source of circulating 
ANGPTL829,288. The expression of ANGPTL8 was heavily repressed during 
inflammatory conditions, as well as the expression of GLUT4, ADIPOQ, 
DGAT1 and FASN. Also, ANGPTL8 gene expression displayed a 
significant negative correlation with the AT inflammatory marker 
PLA2G733,244-246 in morbidly obese pre-bariatric surgery patients. It is 
established that inflammation is a key contributor to adipocyte insulin 
resistance96,289,290. Therefore, we speculate that suppression of ANGPTL8 
expression under inflammatory conditions may significantly affect 
adipocyte lipid metabolism and could also be driving adipocytes towards 
insulin resistance upon AT inflammation. miRNAs are actively involved in 
regulating various biological events including metabolism. Upregulation 
of many miRNAs have been reported during inflammation in obese 
and/or diabetic subjects160,291,292. We investigated whether inflammation 
could regulate ANGPTL8 expression via miRNAs. Hence, we screened the 
3’UTR sequence of ANGPTL8 and discovered many potential miRNA 
binging sites, out of which we shortlisted three miRNAs: miR-107, miR-
143-3p and miR-221-3p based on their previously reported involvement 
in insulin resistance of AT192,293,294. Among these three, miR-221-3p was 
significantly increased under inflammatory stimulus in primary 
adipocytes and positively correlated with the prominent inflammatory 
marker PLA2G7 in the pre-bariatric surgery cohort. Hence, we focused 
our study on miR-221-3p. Using dual luciferase assay with Luc-ANGPTL8 
3’UTR constructs and miR-221-3p mimics, we demonstrated that miR-
221-3p directly binds the ANGPTL8 3’UTR. This result was further 
strengthened by the follow-up experiment where miR-221-3p 
significantly suppressed the endogenous ANGPTL8 protein expression 
and TG storage in SGBS adipocytes. Several studies have shown that miR-
221, a 5’ product of miR-221 pre-miRNA also supresses adiponectin 
receptor-1 causing altered adiponectin signalling and insulin sensitivity of 
adipocytes192. miR-222, additional member of the miR-221/222 family, 
supresses GLUT4 expression and may eventually affect insulin sensitivity 
in gestational diabetes193. This suggests that the miR-221/222 family 
plays a pivotal role in the regulation of adipocyte insulin sensitivity and 
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metabolism158,191. We found a negative correlation between miR-221-3p 
and ANGPTL8 expression in SAT of morbidly obese subset of cohort III 
prior to bariatric surgery, which, interestingly, disappeared after surgery-
induced weight loss, concurrent with improved dyslipidaemia and insulin 
sensitivity along with lowered miR-221-3p expression. These substantial 
evidences suggest that miR-221-3p is a significant regulator of ANGPTL8 
under physiological conditions like severe obesity and inflammation. 
Improved inflammatory and metabolic condition along with loss of the 
above correlation after weight loss suggests that, under these conditions, 
additional mechanisms other than miR-221-3p might dominate in the 
regulation of ANGPTL8 expression. In the future, the correlation of AT 
miR-221-3p and ANGPTL8 should be studied at the protein level. 
 
In this study, we investigated the function of ANGPTL8 in adipocytes. 
First, we generated a pool of stable Angptl8 knock-down (Angptl8 KD) 
3T3-L1 adipocytes through lentivirus- mediated shRNA expression. 
Angptl8 KD resulted in reduced TG storage. Several studies have 
previously implicated the upregulation of ANGPTL8 expression during 
adipocyte differentiation27,295 and upon treatment with insulin which 
facilitates the storage of TG27,34,295. In a formerly published study by Ren 
et al27, transient siRNA-mediated knockdown of Angptl8 in 3T3-L1 
adipocytes led to a defect in adipocytic differentiation. Our stable Angptl8 
knockdown 3T3-L1 adipocytes displayed rather a mild reduction in TG 
storage. However, this effect could be the result of a delicate defect in 
terminal differentiation of the adipocytes. 
Lipidome analysis of Angptl8 KD cells revealed a marked decline in alkyl-
PCs and PE plasmalogens with an ether-linked FA chain, generally in the 
sn-1 position. Biosynthesis of ether phospholipids is initiated by a 
peroxisomal enzyme cascade296. Hence, we speculated that loss of 
Angptl8 may result in a malfunction of peroxisomes. Alkyl glycerol lipids 
serve as natural adipocyte differentiation factors and external addition of 
these lipid species promotes adipocytic differentiation in 3T3-L1297. 
Similarly, Pex7 KO mice lacking plasmalogens show lower body fat with 
characteristic small LDs in both brown and white fat298. Further, we 
observed reduced amounts of saturated PCs and PEs (rare lipid species). 
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There were no significant changes found in the total saturation degree of 
phospholipids. The reason for this observation remain elusive. However, 
a lowered content of ether phospholipids tends to reduce cellular 
membrane fluidity299,300, and reduction of saturated PCs and PEs could be 
a compensatory mechanism to counteract a change in membrane fluidity. 
One of the important findings of Angptl8 knockdown was enhanced 
lipolysis in 3T3-L1 adipocytes, suggesting an endogenous function of 
Angptl8 as an inhibitor of lipolysis. This in line with the earlier reports 
where Angptl8 is highly induced by insulin34,301. Suppression of stored TG 
hydrolysis may occur instantaneously even during the process of FA 
deposition as TGs in WAT. This suggests that Angptl8, analogous to its 
function in the circulation29,213, could act as an intra- cellular inhibitor of 
lipolysis. We did not observe any changes in mRNA expressions of the 
lipolytic genes, ATGL and HSL. However, a mild increase of Angptl4 
mRNA expression was detected. Angptl4 stimulates adipocyte lipolysis302; 
hence its upregulation could have been resulted in increased lipolysis. 
Among the two Angptl8 knockdown (KD1 and KD2) cell pools, KD1 
showed relatively stronger lipolysis than KD2, and also a marked 
elevation of PNPLA3 message was noted. PNPLA3 has been shown to 
increase lipolysis and TG remodelling in hepatocytes303,304. Elevated 
expression of PNPLA3 could have caused increased in lipolysis in KD1. At 
the moment, we are unable to conclude the reason behind the observed 
discrepancy between KD1 and KD2. However, we speculate that putative 
off-target effects of the shRNA could have alleviated the lipolysis effect in 
KD2. Plasmalogens serve as a source of prostaglandin E2 (PGE2) which 
serves as an inhibitor of lipolysis in adipocytes305,306. Reduced amounts of 
PGE2 increase the cellular cAMP leading to enhanced lipolysis307. Also, 
patients with Zellweger syndrome, a genetic peroxisome disorder, display 
a plasmalogen deficiency308.  
We noticed a strong induction of the leptin gene in the Angptl8 KD cell 
pools under basal conditions. However, the mRNA was barely expressed 
under the lipolytic conditions employed. This outcome is debatable since 
PGE2 has been reported to increase leptin secretion by adipocytes306,309. 
Hence, the observed induction of leptin mRNA could signify a 
compensatory response to downregulate the synthesis of PGE2. 
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Alternatively, knockdown of Angptl8 might influence leptin expression 
via another, as yet unknown mechanism. Along with the lipolysis 
phenotype, we also detected several genes associated with FA oxidation 
significantly induced in the Angptl8 KD cell pools. This is in line with the 
observed upregulation of lipolysis releasing free FAs, which can be 
utilized as an energy source through oxidation and further must be 
degraded to minimize the FFA-mediated cellular lipid toxicity310.
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7. CONCLUSIONS 
Evidence suggests that miRNAs are crucial for adipose tissue function. 
Defects in miRNA expression cause impairment of fundamental functions 
of adipocytes, such as differentiation, metabolism, and signalling. This 
influences the AT cellularity and size, which in turn leads to unusual fat 
accumulation and results in the metabolic disorders. miRNAs regulate AT 
endocrine function by regulating the expression of adipokines and their 
signalling pathways. Moreover, miRNAs are actively involved in the 
crosstalk between adipocytes and immune cells within AT. 
In this thesis, we have studied the expression and characterized the 
function of miR-192* in the VAT of human cohorts and in cultured 
adipocytes, respectively. VAT miR-192* expression negatively correlated 
with serum TG and positively with HDL in morbidly obese group and 
negative correlation with BMI was recorded in a less obese cohort. Stable 
overexpression of miR-192* in cultured adipocytes resulted in reduced 
TG accumulation and reduced the expression of key adipogenic and 
lipogenic genes.  miR-221-3p, which had previously been shown to be 
associated with metabolic disorders, was shown to be induced upon 
inflammatory conditions in adipocytes and to directly target ANGPTL8. 
We showed that ANGPTL8, a well-documented regulator of lipid 
metabolism, negatively correlated with miR-221-3p and the AT 
inflammatory gene PLA2G7 in SAT of a morbidly obese human cohort. 
Depletion of ANGPTL8 in cultured adipocytes resulted in the 
enhancement of intracellular lipolysis and an altered ether phospholipid 
content. With the gathered evidence, we have shed light on the roles of 
miR-192*, miR-221-3p and ANGPTL8 as regulators of adipose tissue lipid 
metabolism. 
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